LayerRx Mapping ID
240
Slot System
Featured Buckets
Featured Buckets Admin
Reverse Chronological Sort
Allow Teaser Image
Medscape Lead Concept
8

Caprylate and acetate levels in breast milk and infantile atopic dermatitis: Is there a link?

Article Type
Changed
Mon, 04/04/2022 - 11:15

Key clinical point: Lower levels of caprylate and acetate in breast milk could be risk factors for infantile atopic dermatitis (AD) in exclusively breastfed infants.

Major finding: Caprylate (P = .034) and acetate (P = .002) levels were significantly lower in breast milk for infants with vs. without AD, with caprylate (P = .021) and acetate (P = .015) levels in breast milk being the factors significantly associated with the presence of infantile AD.

Study details: This prospective, observational study included 94 2- to 4-month-old exclusively breastfed infants. In this group 47 infants were diagnosed with mild (n = 17), moderate (n = 25), or severe (n = 5) AD and 47 infants without AD formed the control group.

Disclosures: This study was supported by National Taiwan University Hospital, Taipei, Taiwan. The authors declared no conflict of interests.

Source: Wang LC et al. Lower caprylate and acetate levels in the breast milk is associated with atopic dermatitis in infancy. Pediatr Allergy Immunol. 2022;33(2) e13744 (Feb 21). Doi:  10.1111/pai.13744

 

 

Publications
Topics
Sections

Key clinical point: Lower levels of caprylate and acetate in breast milk could be risk factors for infantile atopic dermatitis (AD) in exclusively breastfed infants.

Major finding: Caprylate (P = .034) and acetate (P = .002) levels were significantly lower in breast milk for infants with vs. without AD, with caprylate (P = .021) and acetate (P = .015) levels in breast milk being the factors significantly associated with the presence of infantile AD.

Study details: This prospective, observational study included 94 2- to 4-month-old exclusively breastfed infants. In this group 47 infants were diagnosed with mild (n = 17), moderate (n = 25), or severe (n = 5) AD and 47 infants without AD formed the control group.

Disclosures: This study was supported by National Taiwan University Hospital, Taipei, Taiwan. The authors declared no conflict of interests.

Source: Wang LC et al. Lower caprylate and acetate levels in the breast milk is associated with atopic dermatitis in infancy. Pediatr Allergy Immunol. 2022;33(2) e13744 (Feb 21). Doi:  10.1111/pai.13744

 

 

Key clinical point: Lower levels of caprylate and acetate in breast milk could be risk factors for infantile atopic dermatitis (AD) in exclusively breastfed infants.

Major finding: Caprylate (P = .034) and acetate (P = .002) levels were significantly lower in breast milk for infants with vs. without AD, with caprylate (P = .021) and acetate (P = .015) levels in breast milk being the factors significantly associated with the presence of infantile AD.

Study details: This prospective, observational study included 94 2- to 4-month-old exclusively breastfed infants. In this group 47 infants were diagnosed with mild (n = 17), moderate (n = 25), or severe (n = 5) AD and 47 infants without AD formed the control group.

Disclosures: This study was supported by National Taiwan University Hospital, Taipei, Taiwan. The authors declared no conflict of interests.

Source: Wang LC et al. Lower caprylate and acetate levels in the breast milk is associated with atopic dermatitis in infancy. Pediatr Allergy Immunol. 2022;33(2) e13744 (Feb 21). Doi:  10.1111/pai.13744

 

 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Atopic Dermatitis April 2022
Gate On Date
Wed, 02/23/2022 - 18:00
Un-Gate On Date
Wed, 02/23/2022 - 18:00
Use ProPublica
CFC Schedule Remove Status
Wed, 02/23/2022 - 18:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
325140.4
Activity ID
77941
Product Name
Clinical Edge Journal Scan
Product ID
124
Supporter Name /ID
RINVOQ [ 5260 ]

Atopic dermatitis: Patients treated with dupilumab at higher risk of developing conjunctivitis

Article Type
Changed
Mon, 04/04/2022 - 11:15

Key clinical point: Patients with atopic dermatitis (AD) who initiated dupilumab were at a 2-fold higher risk of developing conjunctivitis within 6 months of treatment initiation vs. those who initiated other systemic therapies, with comorbid asthma further increasing the risk.

Major finding: The risk of developing conjunctivitis within 6 months of treatment initiation was higher with dupilumab vs. methotrexate (relative risk [RR] 2.12; 95% CI 1.56-2.91), mycophenolate (RR 2.43; 95% CI 1.32-4.47), or cyclosporine (RR 1.83; 95% CI 1.05-3.20). Comorbid asthma could be a risk factor for conjunctivitis in dupilumab initiators (RR 2.86; 95% CI 1.24-6.60).

Study details: This population-based longitudinal study included 5,004,117 patients with AD who newly initiated dupilumab or methotrexate (cohort 1, n = 5,770), dupilumab or mycophenolate (cohort 2, n = 4,402), and dupilumab or cyclosporine (cohort 3, n = 4,238).

Disclosures: This study was supported by the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. The authors declared serving as advisors, speakers, consultants, or principal investigators or receiving funding and grants from several sources.

Source: Schneeweiss MC et al. Incidence of bacterial and nonbacterial conjunctivitis in patients with atopic dermatitis treated with dupilumab: A US multidatabase cohort study. Dermatitis. 2022 (Feb 15). Doi: 10.1097/DER.0000000000000843

 

 

 

Publications
Topics
Sections

Key clinical point: Patients with atopic dermatitis (AD) who initiated dupilumab were at a 2-fold higher risk of developing conjunctivitis within 6 months of treatment initiation vs. those who initiated other systemic therapies, with comorbid asthma further increasing the risk.

Major finding: The risk of developing conjunctivitis within 6 months of treatment initiation was higher with dupilumab vs. methotrexate (relative risk [RR] 2.12; 95% CI 1.56-2.91), mycophenolate (RR 2.43; 95% CI 1.32-4.47), or cyclosporine (RR 1.83; 95% CI 1.05-3.20). Comorbid asthma could be a risk factor for conjunctivitis in dupilumab initiators (RR 2.86; 95% CI 1.24-6.60).

Study details: This population-based longitudinal study included 5,004,117 patients with AD who newly initiated dupilumab or methotrexate (cohort 1, n = 5,770), dupilumab or mycophenolate (cohort 2, n = 4,402), and dupilumab or cyclosporine (cohort 3, n = 4,238).

Disclosures: This study was supported by the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. The authors declared serving as advisors, speakers, consultants, or principal investigators or receiving funding and grants from several sources.

Source: Schneeweiss MC et al. Incidence of bacterial and nonbacterial conjunctivitis in patients with atopic dermatitis treated with dupilumab: A US multidatabase cohort study. Dermatitis. 2022 (Feb 15). Doi: 10.1097/DER.0000000000000843

 

 

 

Key clinical point: Patients with atopic dermatitis (AD) who initiated dupilumab were at a 2-fold higher risk of developing conjunctivitis within 6 months of treatment initiation vs. those who initiated other systemic therapies, with comorbid asthma further increasing the risk.

Major finding: The risk of developing conjunctivitis within 6 months of treatment initiation was higher with dupilumab vs. methotrexate (relative risk [RR] 2.12; 95% CI 1.56-2.91), mycophenolate (RR 2.43; 95% CI 1.32-4.47), or cyclosporine (RR 1.83; 95% CI 1.05-3.20). Comorbid asthma could be a risk factor for conjunctivitis in dupilumab initiators (RR 2.86; 95% CI 1.24-6.60).

Study details: This population-based longitudinal study included 5,004,117 patients with AD who newly initiated dupilumab or methotrexate (cohort 1, n = 5,770), dupilumab or mycophenolate (cohort 2, n = 4,402), and dupilumab or cyclosporine (cohort 3, n = 4,238).

Disclosures: This study was supported by the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. The authors declared serving as advisors, speakers, consultants, or principal investigators or receiving funding and grants from several sources.

Source: Schneeweiss MC et al. Incidence of bacterial and nonbacterial conjunctivitis in patients with atopic dermatitis treated with dupilumab: A US multidatabase cohort study. Dermatitis. 2022 (Feb 15). Doi: 10.1097/DER.0000000000000843

 

 

 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Atopic Dermatitis April 2022
Gate On Date
Wed, 02/23/2022 - 18:00
Un-Gate On Date
Wed, 02/23/2022 - 18:00
Use ProPublica
CFC Schedule Remove Status
Wed, 02/23/2022 - 18:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
325140.4
Activity ID
77941
Product Name
Clinical Edge Journal Scan
Product ID
124
Supporter Name /ID
RINVOQ [ 5260 ]

Atopic dermatitis: Dupilumab safe and effective in real world

Article Type
Changed
Mon, 04/04/2022 - 11:15

Key clinical point: Dupilumab effectively reduced signs and symptoms of atopic dermatitis (AD) along with a tolerable safety profile in a real-world setting during the COVID-19 pandemic.

Major finding: At least 75% improvement in the Eczema Area and Severity Index was achieved by 66.6%, 89.5%, and 95.8% patients at 16 weeks, 1 year, and 2 years of dupilumab therapy, respectively, with persistence rates being >90% throughout the 2 years of therapy. The most reported adverse events were infections, with a mild course of COVID-19 being the most reported (4.7%), followed by ocular complications (2.5%).

Study details: Findings are from a retrospective, multicenter study including 360 adults with severe AD who received ≥1 dose of dupilumab.

Disclosures: This study did not receive any funding. Some authors declared serving as a consultant, speaker, or investigator for several sources.

Source: Kojanova M et al. Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry. J Dermatolog Treat. 2022 (Feb 21). Doi: 10.1080/09546634.2022.2043545

 

 

Publications
Topics
Sections

Key clinical point: Dupilumab effectively reduced signs and symptoms of atopic dermatitis (AD) along with a tolerable safety profile in a real-world setting during the COVID-19 pandemic.

Major finding: At least 75% improvement in the Eczema Area and Severity Index was achieved by 66.6%, 89.5%, and 95.8% patients at 16 weeks, 1 year, and 2 years of dupilumab therapy, respectively, with persistence rates being >90% throughout the 2 years of therapy. The most reported adverse events were infections, with a mild course of COVID-19 being the most reported (4.7%), followed by ocular complications (2.5%).

Study details: Findings are from a retrospective, multicenter study including 360 adults with severe AD who received ≥1 dose of dupilumab.

Disclosures: This study did not receive any funding. Some authors declared serving as a consultant, speaker, or investigator for several sources.

Source: Kojanova M et al. Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry. J Dermatolog Treat. 2022 (Feb 21). Doi: 10.1080/09546634.2022.2043545

 

 

Key clinical point: Dupilumab effectively reduced signs and symptoms of atopic dermatitis (AD) along with a tolerable safety profile in a real-world setting during the COVID-19 pandemic.

Major finding: At least 75% improvement in the Eczema Area and Severity Index was achieved by 66.6%, 89.5%, and 95.8% patients at 16 weeks, 1 year, and 2 years of dupilumab therapy, respectively, with persistence rates being >90% throughout the 2 years of therapy. The most reported adverse events were infections, with a mild course of COVID-19 being the most reported (4.7%), followed by ocular complications (2.5%).

Study details: Findings are from a retrospective, multicenter study including 360 adults with severe AD who received ≥1 dose of dupilumab.

Disclosures: This study did not receive any funding. Some authors declared serving as a consultant, speaker, or investigator for several sources.

Source: Kojanova M et al. Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry. J Dermatolog Treat. 2022 (Feb 21). Doi: 10.1080/09546634.2022.2043545

 

 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Atopic Dermatitis April 2022
Gate On Date
Wed, 02/23/2022 - 18:00
Un-Gate On Date
Wed, 02/23/2022 - 18:00
Use ProPublica
CFC Schedule Remove Status
Wed, 02/23/2022 - 18:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
325140.4
Activity ID
77941
Product Name
Clinical Edge Journal Scan
Product ID
124
Supporter Name /ID
RINVOQ [ 5260 ]

Age and sex determine risk for acne in patients with atopic dermatitis

Article Type
Changed
Mon, 04/04/2022 - 11:15

Key clinical point: Risk for acne was comparable in adolescents and adults with atopic dermatitis (AD) and matched reference individuals from the general population; however, the risk varied with age and sex, with males and older patients appearing to be at higher risk.

Major finding: Although the overall risk for acne was similar among patients with AD vs. reference individuals (hazard ratio [HR] 0.96; P = .4623), the risk was significantly higher in males with AD (HR 1.22; P = .0234) and in patients aged 30-39 (HR 1.41; P = .0156) and ≥40 (HR 2.07; P = .0002) years.

Study details: Findings are from a prospective cohort study including 6,600 adults and adolescents with AD matched with 66,000 reference individuals without AD.

Disclosures: This study did not receive any funding. The authors declared serving as an advisory board member, investigator, speaker, consultant, or receiving honoraria, fees, research funding, and research support from several sources.

Source: Thyssen JP et al. Incidence, prevalence and risk of acne in adolescent and adult patients with atopic dermatitis: a matched cohort study. J Eur Acad Dermatol Venereol. 2022 (Feb 26). Doi: 10.1111/jdv.18027

 

Publications
Topics
Sections

Key clinical point: Risk for acne was comparable in adolescents and adults with atopic dermatitis (AD) and matched reference individuals from the general population; however, the risk varied with age and sex, with males and older patients appearing to be at higher risk.

Major finding: Although the overall risk for acne was similar among patients with AD vs. reference individuals (hazard ratio [HR] 0.96; P = .4623), the risk was significantly higher in males with AD (HR 1.22; P = .0234) and in patients aged 30-39 (HR 1.41; P = .0156) and ≥40 (HR 2.07; P = .0002) years.

Study details: Findings are from a prospective cohort study including 6,600 adults and adolescents with AD matched with 66,000 reference individuals without AD.

Disclosures: This study did not receive any funding. The authors declared serving as an advisory board member, investigator, speaker, consultant, or receiving honoraria, fees, research funding, and research support from several sources.

Source: Thyssen JP et al. Incidence, prevalence and risk of acne in adolescent and adult patients with atopic dermatitis: a matched cohort study. J Eur Acad Dermatol Venereol. 2022 (Feb 26). Doi: 10.1111/jdv.18027

 

Key clinical point: Risk for acne was comparable in adolescents and adults with atopic dermatitis (AD) and matched reference individuals from the general population; however, the risk varied with age and sex, with males and older patients appearing to be at higher risk.

Major finding: Although the overall risk for acne was similar among patients with AD vs. reference individuals (hazard ratio [HR] 0.96; P = .4623), the risk was significantly higher in males with AD (HR 1.22; P = .0234) and in patients aged 30-39 (HR 1.41; P = .0156) and ≥40 (HR 2.07; P = .0002) years.

Study details: Findings are from a prospective cohort study including 6,600 adults and adolescents with AD matched with 66,000 reference individuals without AD.

Disclosures: This study did not receive any funding. The authors declared serving as an advisory board member, investigator, speaker, consultant, or receiving honoraria, fees, research funding, and research support from several sources.

Source: Thyssen JP et al. Incidence, prevalence and risk of acne in adolescent and adult patients with atopic dermatitis: a matched cohort study. J Eur Acad Dermatol Venereol. 2022 (Feb 26). Doi: 10.1111/jdv.18027

 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Atopic Dermatitis April 2022
Gate On Date
Wed, 02/23/2022 - 18:00
Un-Gate On Date
Wed, 02/23/2022 - 18:00
Use ProPublica
CFC Schedule Remove Status
Wed, 02/23/2022 - 18:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
325140.4
Activity ID
77941
Product Name
Clinical Edge Journal Scan
Product ID
124
Supporter Name /ID
RINVOQ [ 5260 ]

Disease severity predicts persistent sleep disturbance from atopic dermatitis

Article Type
Changed
Mon, 04/04/2022 - 11:15

Key clinical point: A significant proportion of patients with atopic dermatitis (AD) experience sleep disturbance (SD), which usually improves overtime; however, patients with moderate-to-severe AD are more likely to experience a persistent SD course.

Major finding: At least 3 nights of SD were reported by 34.2% of patients at baseline; however only 12.3% of patients reported persistent SD at the first and second follow-ups, and only 11.5% of patients with severe SD at baseline experienced persistent SD scores at the second follow-up. Severe/very severe AD vs. mild AD was a significant predictor of increased nights of SD by eczema (adjusted odds ratio 16.20; P < .0001).

Study details: This prospective, dermatology practice-based study included 1,295 patients with mild (40.5%), moderate (35.1%), or severe/very severe (24.4%) AD.

Disclosures: This study was supported by the Agency for Healthcare Research and Quality, the Dermatology Foundation, and an unrestricted research grant from Galderma. R Chavda and S Gabriel declared being employees of and JI Silverberg declared being a consultant for Galderma.

Source: Manjunath J et al. longitudinal course of sleep disturbance and relationship with itch in adult atopic dermatitis in clinical practice. Dermatitis. 2022 (Mar 3). Doi: 10.1097/DER.0000000000000859

Publications
Topics
Sections

Key clinical point: A significant proportion of patients with atopic dermatitis (AD) experience sleep disturbance (SD), which usually improves overtime; however, patients with moderate-to-severe AD are more likely to experience a persistent SD course.

Major finding: At least 3 nights of SD were reported by 34.2% of patients at baseline; however only 12.3% of patients reported persistent SD at the first and second follow-ups, and only 11.5% of patients with severe SD at baseline experienced persistent SD scores at the second follow-up. Severe/very severe AD vs. mild AD was a significant predictor of increased nights of SD by eczema (adjusted odds ratio 16.20; P < .0001).

Study details: This prospective, dermatology practice-based study included 1,295 patients with mild (40.5%), moderate (35.1%), or severe/very severe (24.4%) AD.

Disclosures: This study was supported by the Agency for Healthcare Research and Quality, the Dermatology Foundation, and an unrestricted research grant from Galderma. R Chavda and S Gabriel declared being employees of and JI Silverberg declared being a consultant for Galderma.

Source: Manjunath J et al. longitudinal course of sleep disturbance and relationship with itch in adult atopic dermatitis in clinical practice. Dermatitis. 2022 (Mar 3). Doi: 10.1097/DER.0000000000000859

Key clinical point: A significant proportion of patients with atopic dermatitis (AD) experience sleep disturbance (SD), which usually improves overtime; however, patients with moderate-to-severe AD are more likely to experience a persistent SD course.

Major finding: At least 3 nights of SD were reported by 34.2% of patients at baseline; however only 12.3% of patients reported persistent SD at the first and second follow-ups, and only 11.5% of patients with severe SD at baseline experienced persistent SD scores at the second follow-up. Severe/very severe AD vs. mild AD was a significant predictor of increased nights of SD by eczema (adjusted odds ratio 16.20; P < .0001).

Study details: This prospective, dermatology practice-based study included 1,295 patients with mild (40.5%), moderate (35.1%), or severe/very severe (24.4%) AD.

Disclosures: This study was supported by the Agency for Healthcare Research and Quality, the Dermatology Foundation, and an unrestricted research grant from Galderma. R Chavda and S Gabriel declared being employees of and JI Silverberg declared being a consultant for Galderma.

Source: Manjunath J et al. longitudinal course of sleep disturbance and relationship with itch in adult atopic dermatitis in clinical practice. Dermatitis. 2022 (Mar 3). Doi: 10.1097/DER.0000000000000859

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Atopic Dermatitis April 2022
Gate On Date
Wed, 02/23/2022 - 18:00
Un-Gate On Date
Wed, 02/23/2022 - 18:00
Use ProPublica
CFC Schedule Remove Status
Wed, 02/23/2022 - 18:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
325140.4
Activity ID
77941
Product Name
Clinical Edge Journal Scan
Product ID
124
Supporter Name /ID
RINVOQ [ 5260 ]

Atopic dermatitis and serum lipids: What is the link?

Article Type
Changed
Mon, 04/04/2022 - 11:15

Key clinical point: Atopic dermatitis (AD) was negatively associated with some serum lipids, indicating AD being intrinsically protective for dyslipidemia.

Major finding: AD was significantly associated with lower levels of total cholesterol (β −0.004; P < .001), triglycerides (β −0.006; P = .006), and low-density lipoprotein (β −0.004; P < .001) but not with high-density lipoprotein (P = .794).

Study details: The data come from a large-scale, cross-sectional study including 13,822 patients with AD and 67,896 patients with asthma.

Disclosures: This study was supported by the National Key Research and Development Project of China Precision Medicine Initiative and the Program of Introducing Talents of Discipline to Universities. The authors declared no conflict of interests.

Source: Tang Z et al. Association between atopic dermatitis, asthma, and serum lipids: A UK Biobank based observational study and Mendelian randomization analysis. Front Med. 2022 (Feb 21). Doi: 10.3389/fmed.2022.810092

 

Publications
Topics
Sections

Key clinical point: Atopic dermatitis (AD) was negatively associated with some serum lipids, indicating AD being intrinsically protective for dyslipidemia.

Major finding: AD was significantly associated with lower levels of total cholesterol (β −0.004; P < .001), triglycerides (β −0.006; P = .006), and low-density lipoprotein (β −0.004; P < .001) but not with high-density lipoprotein (P = .794).

Study details: The data come from a large-scale, cross-sectional study including 13,822 patients with AD and 67,896 patients with asthma.

Disclosures: This study was supported by the National Key Research and Development Project of China Precision Medicine Initiative and the Program of Introducing Talents of Discipline to Universities. The authors declared no conflict of interests.

Source: Tang Z et al. Association between atopic dermatitis, asthma, and serum lipids: A UK Biobank based observational study and Mendelian randomization analysis. Front Med. 2022 (Feb 21). Doi: 10.3389/fmed.2022.810092

 

Key clinical point: Atopic dermatitis (AD) was negatively associated with some serum lipids, indicating AD being intrinsically protective for dyslipidemia.

Major finding: AD was significantly associated with lower levels of total cholesterol (β −0.004; P < .001), triglycerides (β −0.006; P = .006), and low-density lipoprotein (β −0.004; P < .001) but not with high-density lipoprotein (P = .794).

Study details: The data come from a large-scale, cross-sectional study including 13,822 patients with AD and 67,896 patients with asthma.

Disclosures: This study was supported by the National Key Research and Development Project of China Precision Medicine Initiative and the Program of Introducing Talents of Discipline to Universities. The authors declared no conflict of interests.

Source: Tang Z et al. Association between atopic dermatitis, asthma, and serum lipids: A UK Biobank based observational study and Mendelian randomization analysis. Front Med. 2022 (Feb 21). Doi: 10.3389/fmed.2022.810092

 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Atopic Dermatitis April 2022
Gate On Date
Wed, 02/23/2022 - 18:00
Un-Gate On Date
Wed, 02/23/2022 - 18:00
Use ProPublica
CFC Schedule Remove Status
Wed, 02/23/2022 - 18:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
325140.4
Activity ID
77941
Product Name
Clinical Edge Journal Scan
Product ID
124
Supporter Name /ID
RINVOQ [ 5260 ]

Moisturizer containing urea and glycerol shows skin barrier-strengthening effects in atopic dermatitis

Article Type
Changed
Mon, 04/04/2022 - 11:15

Key clinical point: A 4-week treatment with a test cream (TC) containing only 2% urea and 20% glycerol significantly reduced sodium lauryl sulphate-induced skin irritation in patients with atopic dermatitis (AD) compared with a no treatment control (NTC) and two reference creams.

Major finding: After 28 days, there was a significant reduction in transepidermal water loss with TC vs. NTC (P < .001), paraffin cream (P < .001), and glycerol cream (P = .021); objective redness was lower with TC vs. NTC (P = .002) and paraffin cream (P < .001). The TC was well tolerated with no evidence of stinging or redness.

Study details: Findings are from a phase 2 trial including 49 adults with AD who were randomly assigned to receive either a TC containing urea and glycerol, a glycerol-containing moisturizer, a simple paraffin cream containing no humectant, or NTC.

Disclosures: This study was funded by Perrigo Nordic. The authors declared serving as consultants, investigators, or advisory board members for and receiving research grants from several sources. Three authors declared being employees of Perrigo Nordic.

Source: Danby SG et al. Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis. Clin Exp Dermatol. 2022 (Feb 15). Doi:  10.1111/ced.15141

Publications
Topics
Sections

Key clinical point: A 4-week treatment with a test cream (TC) containing only 2% urea and 20% glycerol significantly reduced sodium lauryl sulphate-induced skin irritation in patients with atopic dermatitis (AD) compared with a no treatment control (NTC) and two reference creams.

Major finding: After 28 days, there was a significant reduction in transepidermal water loss with TC vs. NTC (P < .001), paraffin cream (P < .001), and glycerol cream (P = .021); objective redness was lower with TC vs. NTC (P = .002) and paraffin cream (P < .001). The TC was well tolerated with no evidence of stinging or redness.

Study details: Findings are from a phase 2 trial including 49 adults with AD who were randomly assigned to receive either a TC containing urea and glycerol, a glycerol-containing moisturizer, a simple paraffin cream containing no humectant, or NTC.

Disclosures: This study was funded by Perrigo Nordic. The authors declared serving as consultants, investigators, or advisory board members for and receiving research grants from several sources. Three authors declared being employees of Perrigo Nordic.

Source: Danby SG et al. Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis. Clin Exp Dermatol. 2022 (Feb 15). Doi:  10.1111/ced.15141

Key clinical point: A 4-week treatment with a test cream (TC) containing only 2% urea and 20% glycerol significantly reduced sodium lauryl sulphate-induced skin irritation in patients with atopic dermatitis (AD) compared with a no treatment control (NTC) and two reference creams.

Major finding: After 28 days, there was a significant reduction in transepidermal water loss with TC vs. NTC (P < .001), paraffin cream (P < .001), and glycerol cream (P = .021); objective redness was lower with TC vs. NTC (P = .002) and paraffin cream (P < .001). The TC was well tolerated with no evidence of stinging or redness.

Study details: Findings are from a phase 2 trial including 49 adults with AD who were randomly assigned to receive either a TC containing urea and glycerol, a glycerol-containing moisturizer, a simple paraffin cream containing no humectant, or NTC.

Disclosures: This study was funded by Perrigo Nordic. The authors declared serving as consultants, investigators, or advisory board members for and receiving research grants from several sources. Three authors declared being employees of Perrigo Nordic.

Source: Danby SG et al. Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis. Clin Exp Dermatol. 2022 (Feb 15). Doi:  10.1111/ced.15141

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Atopic Dermatitis April 2022
Gate On Date
Wed, 02/23/2022 - 18:00
Un-Gate On Date
Wed, 02/23/2022 - 18:00
Use ProPublica
CFC Schedule Remove Status
Wed, 02/23/2022 - 18:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
325140.4
Activity ID
77941
Product Name
Clinical Edge Journal Scan
Product ID
124
Supporter Name /ID
RINVOQ [ 5260 ]

Upadacitinib shows favorable long-term benefit-risk profile in moderate-to-severe atopic dermatitis

Article Type
Changed
Mon, 04/04/2022 - 11:15

Key clinical point: Upadacitinib showed sustained efficacy through 52 weeks in adults and adolescents with moderate-to-severe atopic dermatitis (AD) along with an acceptable safety profile.

Major finding: At week 52, a 75% improvement in Eczema Area and Severity Index (EASI75) was achieved by 82.0% and 79.1% of patients continuing 15 mg upadacitinib and 84.9% and 84.3% of patients continuing 30 mg upadacitinib in Measure Up 1 and Measure Up 2, respectively. More than 80% of patients who switched from placebo to upadacitinib at week 16 achieved EASI75 at week 52. No new adverse events were reported.

Study details: Findings are from a 52-week analysis of two ongoing phase 3 trials, Measure Up 1 and Measure Up 2, including 1,609 adults and adolescents with moderate-to-severe AD who were randomly assigned to receive 15 mg upadacitinib once daily, 30 mg upadacitinib, or placebo.

Disclosures: This study was funded by AbbVie. Three authors reported ties with various sources, including AbbVie, with some receiving payments or personal fees and being employees or stockholders of AbbVie.

Source: Simpson EL et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: Analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatol. 2022 (Mar 9). Doi: 10.1001/jamadermatol.2022.0029

 

Publications
Topics
Sections

Key clinical point: Upadacitinib showed sustained efficacy through 52 weeks in adults and adolescents with moderate-to-severe atopic dermatitis (AD) along with an acceptable safety profile.

Major finding: At week 52, a 75% improvement in Eczema Area and Severity Index (EASI75) was achieved by 82.0% and 79.1% of patients continuing 15 mg upadacitinib and 84.9% and 84.3% of patients continuing 30 mg upadacitinib in Measure Up 1 and Measure Up 2, respectively. More than 80% of patients who switched from placebo to upadacitinib at week 16 achieved EASI75 at week 52. No new adverse events were reported.

Study details: Findings are from a 52-week analysis of two ongoing phase 3 trials, Measure Up 1 and Measure Up 2, including 1,609 adults and adolescents with moderate-to-severe AD who were randomly assigned to receive 15 mg upadacitinib once daily, 30 mg upadacitinib, or placebo.

Disclosures: This study was funded by AbbVie. Three authors reported ties with various sources, including AbbVie, with some receiving payments or personal fees and being employees or stockholders of AbbVie.

Source: Simpson EL et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: Analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatol. 2022 (Mar 9). Doi: 10.1001/jamadermatol.2022.0029

 

Key clinical point: Upadacitinib showed sustained efficacy through 52 weeks in adults and adolescents with moderate-to-severe atopic dermatitis (AD) along with an acceptable safety profile.

Major finding: At week 52, a 75% improvement in Eczema Area and Severity Index (EASI75) was achieved by 82.0% and 79.1% of patients continuing 15 mg upadacitinib and 84.9% and 84.3% of patients continuing 30 mg upadacitinib in Measure Up 1 and Measure Up 2, respectively. More than 80% of patients who switched from placebo to upadacitinib at week 16 achieved EASI75 at week 52. No new adverse events were reported.

Study details: Findings are from a 52-week analysis of two ongoing phase 3 trials, Measure Up 1 and Measure Up 2, including 1,609 adults and adolescents with moderate-to-severe AD who were randomly assigned to receive 15 mg upadacitinib once daily, 30 mg upadacitinib, or placebo.

Disclosures: This study was funded by AbbVie. Three authors reported ties with various sources, including AbbVie, with some receiving payments or personal fees and being employees or stockholders of AbbVie.

Source: Simpson EL et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: Analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatol. 2022 (Mar 9). Doi: 10.1001/jamadermatol.2022.0029

 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Atopic Dermatitis April 2022
Gate On Date
Wed, 02/23/2022 - 18:00
Un-Gate On Date
Wed, 02/23/2022 - 18:00
Use ProPublica
CFC Schedule Remove Status
Wed, 02/23/2022 - 18:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
325140.4
Activity ID
77941
Product Name
Clinical Edge Journal Scan
Product ID
124
Supporter Name /ID
RINVOQ [ 5260 ]

The Impact of Prenatal Nutrition on the Development of Atopic Dermatitis in Infancy and Childhood

Article Type
Changed
Tue, 08/09/2022 - 09:43
Display Headline
The Impact of Prenatal Nutrition on the Development of Atopic Dermatitis in Infancy and Childhood

Atopic dermatitis (AD) is an inflammatory skin disease characterized by skin barrier disruption, skin inflammation, and pruritus.1 It is a common and often chronic skin condition associated with the development of food allergies, asthma, and allergic rhinitis, known as the atopic march.2 Atopic dermatitis is estimated to affect 10% to 25% of children, most with onset before 5 years of age, and up to 7% of adults worldwide.3 Most patients improve with time, but multiple disease trajectories are possible. Several studies have demonstrated that fewer than 4% of children develop the classic atopic march—AD followed by food allergies, asthma, and finally allergic rhinitis—with recent evidence pointing to a more complex heterogeneous progression of disease and allergic comorbidities often occurring together.4,5 The prevalence of AD has been increasing globally over the last 30 years,6 with a marked increase in developed countries.6,7 It is well accepted that AD is based on an interplay between genetic predisposition and environmental factors,8 but many suspect that the rapid rise in prevalence cannot be attributed to genetic factors alone.9 The precipitant triggers for AD remain an area of intense investigation, with ongoing debate between the “inside out” and “outside in” hypotheses; these revolve around whether abnormalities in the immune system trigger barrier dysfunction or barrier dysfunction triggers immune programming to atopy.8 Ongoing research related to genetic predisposition of AD has identified candidate genes implicated in both impaired skin barrier function and altered immune system pathways, further supporting that both theories may contribute to disease pathogenesis. 

The increasing prevalence of AD, with increasing disease burden within socioeconomically advantaged countries, raises the possibility of early modifiable environmental factors that may contribute to the disease process.10 Many studies point to the influence of the 21st century lifestyle and Western diet as primary contributing factors.9,11 However, it is not clear how these factors may influence the development of allergic atopic disease. Several studies have suggested that nonheritable influences in utero can alter fetus immune function and influence the subsequent development of allergic disease.12,13 Although many studies have examined environmental factors contributing to the development of AD in infancy and childhood, less is understood about the influence of prenatal factors. Currently, in utero exposure to tobacco smoke, phthalates, and maternal distress have been potentially implicated in the development of AD.14,15 Several studies have examined the role of maternal diet and nutrition on the development of AD in offspring; however, formal recommendations and robust trial data are lacking. In this article, we examine the existing literature surrounding maternal diet on the development of AD in infancy and childhood.

Allergen Avoidance 

Extrapolating from the food allergy literature, it was once suggested that allergen avoidance in early childhood had a protective effect on the subsequent development of allergies; however, more recent research has found that early exposure to common food allergens, such as peanuts or eggs, may actually reduce a child’s risk for developing these allergies later in life.16 Among infants at high risk for food allergy, sustained consumption of peanut products beginning in the first 11 months of life resulted in an 81% lower rate of peanut allergy at 60 months of age than the rate among children who avoided peanuts.17 Given the results that antigen avoidance during infancy/childhood does not protect against the development of allergies and may actually be counterproductive, it is not surprising that research studying antigen avoidance during pregnancy on the development of AD also has demonstrated limited efficacy. A systematic review of 5 trials on maternal dietary antigen avoidance (N=952) suggested no protective effects of avoiding antigenic foods during pregnancy on the development of AD in the first 18 months of life.18 Another meta-analysis evaluating 12 intervention trials looked at the effects of maternal allergenic food avoidance during pregnancy or lactation and found no reduced risk for subsequent development of allergic disease, including AD.19 The American Academy of Pediatrics 2019 consensus statement does not support maternal dietary restrictions in pregnancy for the prevention of atopic disease and makes note that the data remain limited, which complicates drawing any firm conclusions.20

Probiotic Supplementation 

One of the most investigated dietary supplements for the prevention of atopic disease is probiotics, with possible benefits noted in both the prenatal and postnatal periods. Baquerizo Nole et al21 examined several studies looking at the various benefits of probiotics in AD, which included inhibition of the helper T cell (TH2) response, stimulation of the TH1 response, upregulation of regulatory T cells, acceleration of skin and mucosal barrier function, increase in intestinal microflora diversity, suppression of toxic fermentation products in the intestinal lumen from increased production of short-chain fatty acids, and inhibition of Staphylococcus aureus attachment on epidermal keratinocytes. It is unclear how this may affect infants prenatally; however, transfer of maternal intestinal microflora during delivery and shortly thereafter has demonstrated that probiotic strains remain detectable in the infant’s stool up to 6 months after delivery, even if the mother has discontinued use.22 A 2008 meta-analysis of 10 double-bind, randomized, controlled trials (N=1880) looking at the use of maternal prenatal and postnatal probiotic supplementation in the prevention of pediatric AD found a relative risk (RR) ratio of 0.69 (95% CI, 0.57-0.83) using a fixed effects model and RR ratio of 0.66 (95% CI, 0.49-0.89) using a random effects model. After exclusion of one study that evaluated the effect of postnatal probiotic supplementation only, the RR ratio decreased to 0.61 for both the fixed effects and random effects models.23 A systematic review by Panduru et al24 noted similar findings with a subgroup meta-analysis of 11 studies of prenatal supplementation followed by postnatal supplementation of probiotics, which demonstrated a protective effect on the development of AD (odds ratio [OR]=0.61, P<.001). Postnatal supplementation alone (4 studies) did not have the same association (OR=0.95, P<.82).24 A 2012 meta-analysis by Doege et al25 evaluated 7 randomized, double-blinded, placebo-controlled trials that assessed probiotic supplementation during pregnancy (without incorporation of postnatal supplementation) and found a significant risk reduction of 5.7% (P=.022) for AD in children aged 2 to 7 years. Interestingly, this was only significant for Lactobacillus and not for other bacterial strains, even if a mixture of strains included Lactobacillus. However, Panduru et al24 found both maternal Lactobacillus supplementation alone (8 studies) and in combination with Bifidobacterium (9 studies) was protective against AD development in children (OR=0.70, P=.004; OR=0.62, P<.001). A more recent 2015 meta-analysis of 17 studies (N=4755) evaluating the use of maternal probiotic supplementation in pregnancy and/or through the infant’s first 3 months of life found a significantly lower RR (0.78 [95% CI, 0.69-0.89], P=.0003) for the development of AD in infants treated with probiotics and found this risk to be even further decreased when a mixture of probiotics including both Lactobacillus and Bifidobacterium was used (RR=0.54 [95% CI, 0.43-0.68], P<.00001).26

Antioxidants

The Westernization of many developing countries’ diets—diets high in saturated fats, protein, sucrose, salt, and processed foods and low in fresh fruits and green vegetables—has led to a reduced intake of antioxidants and an increase in susceptibility to oxidative damage.27,28 One hypothesis suggests that a reduction in nutritional antioxidants and subsequent oxidative damage leads to airway inflammation that may contribute to an increased prevalence of asthma.27 In vitro data suggest that antioxidant deficiency may influence the differentiation of helper T cells to a TH2 phenotype, which can increase susceptibility to the development of asthma and allergies.29 Vitamin E specifically has been shown to inhibit IL-4 gene expression, which drives type 2 immunity and decreases expression of multiple genes that regulate epidermal barrier function, subsequently increasing susceptibility to allergic inflammation and AD.29,30 Regardless of the proposed mechanisms for antioxidant deficiency increasing susceptibility to allergic disease, studies evaluating the benefits of antioxidant intake during pregnancy in relation to AD have not been promising. Several studies have found no association between prenatal vitamin E intake and the risk for AD development in infants and children.31,32 Another study found a statistically significant inverse relationship between vitamin E intake in mothers with a history of atopy and the development of AD in their children at 2 years of age but not at 1 year of age (P-trend=.024).33 It has been suggested that varying vitamin E isoforms may contribute to the discrepant results previously discussed, with the γ-tocopherol isoform (found frequently in Westernized diets)34 as a driver of inflammation in murine models.35 West et al31 noted an association between vitamin C intake and development of “any allergic disease”—AD, IgE-mediated food allergy, or asthma—with a crude OR of 0.48 (95% CI, 0.25-0.93). However, the P-trend and adjusted OR were not statistically significant. The investigators found no association between maternal intake of beta-carotene, vitamin E, or zinc, but they did find copper supplementation to be protective on the development of AD at 1 year of age (P-trend=0.03). Interestingly, when the data for total antioxidant intake—vitamin C, vitamin E, zinc, beta-carotene, and copper from both diet and supplementation—were combined and analyzed, no statistically significant associations for any of the antioxidants were found.31 Another study of 763 Japanese mother-child pairs found a reduced risk for AD at 16 to 24 months of age with high maternal intake of beta-carotene but found no statistically significant exposure-response associations with other antioxidants, including alpha-carotene, vitamin C, or zinc from dietary intake alone.32 These results were substantiated by 2 meta-analyses evaluating a total of 93 combined intervention trials and cohorts where no association was found between vitamin or mineral intake during pregnancy and/or during infancy and the development of AD.19,36 

Fatty Acids 

Other dietary changes that are associated with an increased prevalence of atopic diseases in children include excess consumption of omega-6 (n-6) long-chain polyunsaturated fatty acids (LC-PUFA) and insufficient omega-3 (n-3) LC-PUFA consumption.37 Given prior evidence that allergic immune responses in infants may be primed before birth,38 researchers have questioned whether the anti-inflammatory properties of n-3 LC-PUFA when supplemented during pregnancy may have immunomodulatory effects on infants that could alter their predisposition to develop allergic disease, including AD.39 A systematic review and meta-analysis of randomized controlled trials found a statistically significant RR of 0.53 (95% CI, 0.35-0.81; P=.004) for the incidence of AD at 12 months of age with maternal supplementation of n-3 LC-PUFA.9 Another trial of 145 pregnant women randomized to supplementation with fish oil vs placebo starting at gestational week 25 and continuing through 3.5 months of breastfeeding found a reduced cumulative incidence of AD in the intervention group compared to controls at 2 years of age, with a statistically significant crude OR of 0.33 (95% CI, 0.11-0.97; P=.04).40 However, the adjusted OR was not statistically significant. In addition, they found that mothers and infants with higher proportions of docosahexaenoic acid and eicosapentaenoic acid in plasma phospholipids have been noted to have a lower prevalence of IgE-associated disease in a dose-dependent manner (P<.05 and P<.05, respectively).40 In another trial of 98 pregnant women randomized to fish oil supplementation or placebo from 20 weeks’ gestation to delivery found no difference in the frequency of AD but did note that infants in the exposure group had significantly less severe AD compared to controls (OR=0.09 [95% CI, 0.1-0.94]; P=.045).39 A prospective birth cohort study of 2641 children evaluated dietary composition during the last 4 weeks of pregnancy and found that consumption of foods rich in n-6 LC-PUFAs (eg, margarine, vegetable oil) increased the risk for developing AD, while foods rich in n-3 LC-PUFAs (eg, fish) decreased the risk for developing AD in offspring at 2 years of age. All P values for margarine, vegetable oil, and fish were statistically significant on logistic regression at P<.05.41 A longitudinal analysis of follow-up data from a randomized controlled trial looking at maternal prenatal n-3 LC-PUFA intake and the development of allergic disease (including AD) found no differences in the development of disease at 1-, 3-, or 6-year follow-up.42 Despite several studies demonstrating a possible benefit of omega-3 fatty acid intake on the development of AD in offspring, the longitudinal analysis by Best et al42 reminds us that long-term follow-up is critical in establishing benefit of any intervention given the heterogeneous and progressive nature of the atopic march and AD. 

Specific Diets 

Several studies have evaluated the role of dietary patterns and their influence on atopic disease. Studies evaluating dietary patterns or supplement intake can be challenging, as data often are derived from questionnaires with bias in response to families with higher socioeconomic status.9 Further, analysis of any one food group does not account for the potential interplay between nutrients.43 Studies should focus more on dietary patterns vs individual foods to assess true risk.43,44 Given these limitations, study results on diet should be carefully scrutinized; however, there are still some positive findings that deserve further investigation. Chatzi et al44 followed 460 children for 6.5 years and found a protective effect for the development of atopy in the offspring of women who had high adherence to the Mediterranean diet (OR 0.55 [95% CI, 0.31-0.97]). Another cohort study evaluating the effects of the Mediterranean diet and risk for AD in the first year of life in 2516 mother-child pairs from Spain and Greece found no statistically significant association with consumption of the Mediterranean diet and AD. The investigators also evaluated intake of fruits, nuts, vegetables, meats, processed meats, dairy products, and cereal and found no statistically significant protective benefit.45 Another systematic review of more than 90 observational studies identified no significant relationship between prenatal dietary exposures of fruits, vegetables, nuts, fat, fatty acids, eggs, cereal, milk, alcohol, tea, or coffee and risk for allergic disease in offspring, including AD.19

 

 

A Chinese prospective cohort study evaluated the dietary protein patterns of 713 mother-child pairs and the incidence of infant AD at 6 months of age.46 Dietary protein patterns were characterized as predominantly poultry, plant based, dairy and eggs, and red meat and fish. The investigators found a statistically significant reduced risk for AD in mothers who consumed plant-based or dairy and eggs protein patterns when compared to a poultry protein pattern with an adjusted OR of 0.572 (95% CI, 0.330-0.992) and 0.478 (95% CI, 0.274-0.837), respectively. This protective effect was not seen with the red meat and fish protein patterns.46 Similar results were seen in a 2020 Canadian study that evaluated the effects of a Western (fats, meats, processed foods, and starchy vegetables), balanced (diverse sources of animal proteins [especially fish], fruits, vegetables, nuts, and seeds), or plant-based (dairy, legumes, vegetables, whole grains, and an aversion to meats) diet in more than 2000 mother-infant pairs from 24 to 28 weeks’ gestation to 1 year of age. The investigators found a lower OR of AD in mothers who followed a mostly plant-based diet compared to other dietary patterns (OR 0.65 [95% CI, 0.55-0.76]; P<.001).10 Another prospective Japanese study looking at healthy (high intake of green and yellow vegetables, seaweed, mushrooms, white vegetables, pulses, potatoes, fish, sea products, fruit, and shellfish, and low intake of confectioneries and soft drinks), Western (high intake of vegetable oil, salt-containing seasonings, beef, pork, processed meat, eggs, chicken, and white vegetables, and low intake of fruit, soft drinks, and confectioneries), or Japanese (high intake of rice, miso soup, sea products, and fish, and low intake of bread, confectioneries, and dairy products) dietary patterns in 763 mother-child pairs found no association between diet during pregnancy and development of AD in offspring at 16 to 24 months.47 Unfortunately, a longitudinal data analysis has not been performed for this study.

Final Thoughts

Atopic dermatitis is a complex, progressive, and heterogeneous disease with both genetic and environmental influences. Studying the effects of diet on the development, progression, or severity of disease can be very difficult due to the heterogeneity of study designs, lack of long-term follow-up, and high potential for residual confounding. Studies evaluating dietary patterns or supplement intake can be equally challenging, as data often are derived from questionnaires with bias in response to families with higher socioeconomic status.9 Very few studies have looked specifically at maternal dietary composition and the development of AD alone (without inclusion of asthma or food allergy). Ultimately, the inconsistency of the data makes it difficult to draw conclusions and make formal recommendations for this vulnerable population. Additional evidence from well-powered trials with comparable methodology and objective outcome measures will be imperative to make formal recommendations. In addition, longitudinal follow-up will be essential to determine long-term benefit and influence on the atopic march.

References
  1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(suppl 1):8-16.
  2. Kapoor R, Menon C, Hoffstad O, et al. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol. 2008;58:68-73.
  3. Abuabara K, Magyari A, McCulloch CE, et al. Prevalence of atopic eczema among patients seen in primary care: data from the Health Improvement Network. Ann Intern Med. 2019;170:354-356.
  4. Belgrave DC, Granell R, Simpson A, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Medicine. 2014;11:E1001748.
  5. Aguilar D, Pinart M, Koppelman GH, et al. Computational analysis of multimorbidity between asthma, eczema and rhinitis. PloS One. 2017;12:E0179125.
  6. Deckers IA, McLean S, Linssen S, et al. Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies. PloS One. 2012;7:E39803.
  7. Williams H, Stewart A, von Mutius E, et al. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008;121:947-954.
  8. Sullivan M, Silverberg NB. Current and emerging concepts in atopic dermatitis pathogenesis. Clin Dermatol. 2017;35:349-353.
  9. Best KP, Gold M, Kennedy D, et al. Omega-3 long-chain PUFA intake during pregnancy and allergic disease outcomes in the offspring: a systematic review and meta-analysis of observational studies and randomized controlled trials. Am J Clin Nutr. 2016;103:128-143.
  10. Zulyniak MA, de Souza RJ, Shaikh M, et al. Ethnic differences in maternal diet in pregnancy and infant eczema. PloS One. 2020;15:E0232170.
  11. Jena PK, Sheng L, Mcneil K, et al. Long-term Western diet intake leads to dysregulated bile acid signaling and dermatitis with Th2 and Th17 pathway features in mice. J Dermatol Sci. 2019;95:13-20.
  12. Grieger JA, Clifton VL, Tuck AR, et al. In utero programming of allergic susceptibility. Int Arch Allergy Immunol. 2016;169:80-92. doi:10.1159/000443961
  13. Khan TK, Palmer DJ, Prescott SL. In-utero exposures and the evolving epidemiology of paediatric allergy. Curr Opin Allergy Clin Immunol. 2015;15:402-408. doi:10.1097/ACI.0000000000000209
  14. Bauer SM. Atopic eczema: genetic associations and potential links to developmental exposures. Int J Toxicol. 2017;36:187-198.
  15. Shinohara M, Saito H, Matsumoto K. Different timings of prenatal or postnatal tobacco smoke exposure have different effects on the development of atopic eczema/dermatitis syndrome (AEDS) during infancy. J Allergy Clin Immunol. 2012;129:AB40.
  16. Lerodiakonou D, Garcia-Larsen V, Logan A, et al. Timing of allergenic food introduction to the infant diet and risk of allergic or autoimmune disease: a systematic review and meta-analysis. JAMA. 2016;316:1181-1192.
  17. Du Toit G, Roberts G, Sayre PH, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372:803-813.
  18. Kramer MS, Kakuma R. Maternal dietary antigen avoidance during pregnancy or lactation, or both, for preventing or treating atopic disease in the child. Evid Based Child Health. 2014;9:447-483.
  19. Garcia-Larsen V, Ierodiakonou D, Jarrold K, et al. Diet during pregnancy and infancy and risk of allergic or autoimmune disease: a systematic review and meta-analysis. PLoS Med. 2018;15:E1002507.
  20. Greer FR, Sicherer SH, Burks AW; Committee on Nutrition, Section on Allergy and Immunology. The effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics. 2019;143:e20190281.
  21. Baquerizo Nole KL, Yim E, Keri JE. Probiotics and prebiotics in dermatology. J Am Acad Dermatol. 2014;71:814-821.
  22. Schultz M, Göttl C, Young RJ, et al. Administration of oral probiotic bacteria to pregnant women causes temporary infantile colonization. J Pediatr Gastroenterol Nutr. 2004;38:293-297.
  23. Lee J, Seto D, Bielory L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol. 2008;121:116-121.
  24. Panduru M, Panduru NM, Sa˘la˘va˘stru CM, et al. Probiotics and primary prevention of atopic dermatitis: a meta‐analysis of randomized controlled studies. J Eur Acad Dermatol Venereol. 2015;29:232-242.
  25. Doege K, Grajecki D, Zyriax BC, et al. Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood—a meta-analysis. Br J Nutr. 2012;107:1-6.
  26. Zuccotti G, Meneghin F, Aceti A, et al. Probiotics for prevention of atopic diseases in infants: systematic review and meta‐analysis. Allergy. 2015;70:1356-1371.
  27. Seaton A, Godden DJ, Brown K. Increase in asthma: a more toxic environment or a more susceptible population? Thorax. 1994;49:171-174.
  28. Manzel A, Muller DN, Hafler DA, et al. Role of “Western diet” in inflammatory autoimmune diseases. Curr Allergy Asthma Rep. 2014;14:1-8.
  29. Li-Weber M, Giasisi M, Trieber MK, et al. Vitamin E inhibits IL-4 gene expression in peripheral blood T cells. Eur J Immunol. 2002;32:2401-2408.
  30. Sehra S, Yao Y, Howell MD, et al. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol. 2010;184:3186-3190.
  31. West CE, Dunstan J, McCarthy S, et al. Associations between maternal antioxidant intakes in pregnancy and infant allergic outcomes. Nutrients. 2012;4:1747-1758.
  32. Miyake Y, Sasaki S, Tanaka K, et al. Consumption of vegetables, fruit, and antioxidants during pregnancy and wheeze and eczema in infants. Allergy. 2010;65:758-765.
  33. Martindale S, McNeill G, Devereux G, et al. Antioxidant intake in pregnancy in relation to wheeze and eczema in the first two years of life. Am J Respir Crit Care Med. 2005;171:121-128.
  34. Robison R, Kumar R. The effect of prenatal and postnatal dietary exposures on childhood development of atopic disease. Curr Opin Allergy Clin Immunol. 2010;10:139-144.
  35. Berdnikovs S, Abdala-Valencia H, McCary C, et al. Isoforms of vitamin E have opposing immunoregulatory functions during inflammation by regulating leukocyte recruitment. J Immunol. 2009;182:4395-4405.
  36. Beckhaus AA, Garcia‐Marcos L, Forno E, et al. Maternal nutrition during pregnancy and risk of asthma, wheeze, and atopic diseases during childhood: a systematic review and meta‐analysis. Allergy. 2015;70:1588-1604.
  37. Calder PC, Miles EA. Fatty acids and atopic disease. Pediatr Allergy Immunol. 2000;11(suppl 13):29-36.
  38. Prescott S, Macaubas C, Holt B, et al. Transplacental priming of the human immune system to environmental allergens: universal skewing of initial T-cell responses towards Th-2 cytokine profile. J Immunol. 1998;160:4730-4737.
  39. Dunstan JA, Mori TA, Barden A, et al. Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: a randomized, controlled trial. J Allergy Clin Immunol. 2003;112:1178-1184.
  40. Furuhjelm C, Warstedt K, Fagerås M, et al. Allergic disease in infants up to 2 years of age in relation to plasma omega‐3 fatty acids and maternal fish oil supplementation in pregnancy and lactation. Pediatr Allergy Immunol. 2011;22:505-514.
  41. Sausenthaler S, Koletzko S, Schaaf B, et al; LISA Study Group. Maternal diet during pregnancy in relation to eczema and allergic sensitization in the offspring at 2 y of age. Am J Clin Nutr. 2007;85:530-537.
  42. Best KP, Sullivan TR, Palmer DJ, et al. Prenatal omega-3 LCPUFA and symptoms of allergic disease and sensitization throughout early childhood—a longitudinal analysis of long-term follow-up of a randomized controlled trial. World Allergy Organ J. 2018;11:10.
  43. Jacobs DR Jr, Steffen LM. Nutrients, foods, and dietary patterns as exposures in research: a framework for food synergy. Am J Clin Nutr. 2003;78:508-513.
  44. Chatzi L, Torrent M, Romieu I, et al. Mediterranean diet in pregnancy is protective for wheeze and atopy in childhood. Thorax. 2008;63:507-513.
  45. Chatzi L, Garcia R, Roumeliotaki T, et al. Mediterranean diet adherence during pregnancy and risk of wheeze and eczema in the first year of life: INMA (Spain) and RHEA (Greece) mother-child cohort studies. Br J Nutr. 2013;110:2058-2068.
  46. Zeng J, Wu W, Chen Y, et al. Maternal dietary protein patterns during pregnancy and the risk of infant eczema: a cohort study. Front Nutr. 2021;8:294.
  47. Miyake Y, Okubo H, Sasaki S, et al. Maternal dietary patterns during pregnancy and risk of wheeze and eczema in Japanese infants aged 16–24 months: the Osaka Maternal and Child Health Study. Pediatr Allergy Immunol. 2011;22:734-741.
Article PDF
Author and Disclosure Information

From the Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison.

The authors report no conflict of interest.

Correspondence: Bridget E. Shields, MD, 1 S Park St, University of Wisconsin School of Medicine and Public Health, Department of Dermatology, Madison, WI 53711 ([email protected]).

Issue
Cutis - 109(3)
Publications
Topics
Page Number
152-156
Sections
Author and Disclosure Information

From the Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison.

The authors report no conflict of interest.

Correspondence: Bridget E. Shields, MD, 1 S Park St, University of Wisconsin School of Medicine and Public Health, Department of Dermatology, Madison, WI 53711 ([email protected]).

Author and Disclosure Information

From the Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison.

The authors report no conflict of interest.

Correspondence: Bridget E. Shields, MD, 1 S Park St, University of Wisconsin School of Medicine and Public Health, Department of Dermatology, Madison, WI 53711 ([email protected]).

Article PDF
Article PDF

Atopic dermatitis (AD) is an inflammatory skin disease characterized by skin barrier disruption, skin inflammation, and pruritus.1 It is a common and often chronic skin condition associated with the development of food allergies, asthma, and allergic rhinitis, known as the atopic march.2 Atopic dermatitis is estimated to affect 10% to 25% of children, most with onset before 5 years of age, and up to 7% of adults worldwide.3 Most patients improve with time, but multiple disease trajectories are possible. Several studies have demonstrated that fewer than 4% of children develop the classic atopic march—AD followed by food allergies, asthma, and finally allergic rhinitis—with recent evidence pointing to a more complex heterogeneous progression of disease and allergic comorbidities often occurring together.4,5 The prevalence of AD has been increasing globally over the last 30 years,6 with a marked increase in developed countries.6,7 It is well accepted that AD is based on an interplay between genetic predisposition and environmental factors,8 but many suspect that the rapid rise in prevalence cannot be attributed to genetic factors alone.9 The precipitant triggers for AD remain an area of intense investigation, with ongoing debate between the “inside out” and “outside in” hypotheses; these revolve around whether abnormalities in the immune system trigger barrier dysfunction or barrier dysfunction triggers immune programming to atopy.8 Ongoing research related to genetic predisposition of AD has identified candidate genes implicated in both impaired skin barrier function and altered immune system pathways, further supporting that both theories may contribute to disease pathogenesis. 

The increasing prevalence of AD, with increasing disease burden within socioeconomically advantaged countries, raises the possibility of early modifiable environmental factors that may contribute to the disease process.10 Many studies point to the influence of the 21st century lifestyle and Western diet as primary contributing factors.9,11 However, it is not clear how these factors may influence the development of allergic atopic disease. Several studies have suggested that nonheritable influences in utero can alter fetus immune function and influence the subsequent development of allergic disease.12,13 Although many studies have examined environmental factors contributing to the development of AD in infancy and childhood, less is understood about the influence of prenatal factors. Currently, in utero exposure to tobacco smoke, phthalates, and maternal distress have been potentially implicated in the development of AD.14,15 Several studies have examined the role of maternal diet and nutrition on the development of AD in offspring; however, formal recommendations and robust trial data are lacking. In this article, we examine the existing literature surrounding maternal diet on the development of AD in infancy and childhood.

Allergen Avoidance 

Extrapolating from the food allergy literature, it was once suggested that allergen avoidance in early childhood had a protective effect on the subsequent development of allergies; however, more recent research has found that early exposure to common food allergens, such as peanuts or eggs, may actually reduce a child’s risk for developing these allergies later in life.16 Among infants at high risk for food allergy, sustained consumption of peanut products beginning in the first 11 months of life resulted in an 81% lower rate of peanut allergy at 60 months of age than the rate among children who avoided peanuts.17 Given the results that antigen avoidance during infancy/childhood does not protect against the development of allergies and may actually be counterproductive, it is not surprising that research studying antigen avoidance during pregnancy on the development of AD also has demonstrated limited efficacy. A systematic review of 5 trials on maternal dietary antigen avoidance (N=952) suggested no protective effects of avoiding antigenic foods during pregnancy on the development of AD in the first 18 months of life.18 Another meta-analysis evaluating 12 intervention trials looked at the effects of maternal allergenic food avoidance during pregnancy or lactation and found no reduced risk for subsequent development of allergic disease, including AD.19 The American Academy of Pediatrics 2019 consensus statement does not support maternal dietary restrictions in pregnancy for the prevention of atopic disease and makes note that the data remain limited, which complicates drawing any firm conclusions.20

Probiotic Supplementation 

One of the most investigated dietary supplements for the prevention of atopic disease is probiotics, with possible benefits noted in both the prenatal and postnatal periods. Baquerizo Nole et al21 examined several studies looking at the various benefits of probiotics in AD, which included inhibition of the helper T cell (TH2) response, stimulation of the TH1 response, upregulation of regulatory T cells, acceleration of skin and mucosal barrier function, increase in intestinal microflora diversity, suppression of toxic fermentation products in the intestinal lumen from increased production of short-chain fatty acids, and inhibition of Staphylococcus aureus attachment on epidermal keratinocytes. It is unclear how this may affect infants prenatally; however, transfer of maternal intestinal microflora during delivery and shortly thereafter has demonstrated that probiotic strains remain detectable in the infant’s stool up to 6 months after delivery, even if the mother has discontinued use.22 A 2008 meta-analysis of 10 double-bind, randomized, controlled trials (N=1880) looking at the use of maternal prenatal and postnatal probiotic supplementation in the prevention of pediatric AD found a relative risk (RR) ratio of 0.69 (95% CI, 0.57-0.83) using a fixed effects model and RR ratio of 0.66 (95% CI, 0.49-0.89) using a random effects model. After exclusion of one study that evaluated the effect of postnatal probiotic supplementation only, the RR ratio decreased to 0.61 for both the fixed effects and random effects models.23 A systematic review by Panduru et al24 noted similar findings with a subgroup meta-analysis of 11 studies of prenatal supplementation followed by postnatal supplementation of probiotics, which demonstrated a protective effect on the development of AD (odds ratio [OR]=0.61, P<.001). Postnatal supplementation alone (4 studies) did not have the same association (OR=0.95, P<.82).24 A 2012 meta-analysis by Doege et al25 evaluated 7 randomized, double-blinded, placebo-controlled trials that assessed probiotic supplementation during pregnancy (without incorporation of postnatal supplementation) and found a significant risk reduction of 5.7% (P=.022) for AD in children aged 2 to 7 years. Interestingly, this was only significant for Lactobacillus and not for other bacterial strains, even if a mixture of strains included Lactobacillus. However, Panduru et al24 found both maternal Lactobacillus supplementation alone (8 studies) and in combination with Bifidobacterium (9 studies) was protective against AD development in children (OR=0.70, P=.004; OR=0.62, P<.001). A more recent 2015 meta-analysis of 17 studies (N=4755) evaluating the use of maternal probiotic supplementation in pregnancy and/or through the infant’s first 3 months of life found a significantly lower RR (0.78 [95% CI, 0.69-0.89], P=.0003) for the development of AD in infants treated with probiotics and found this risk to be even further decreased when a mixture of probiotics including both Lactobacillus and Bifidobacterium was used (RR=0.54 [95% CI, 0.43-0.68], P<.00001).26

Antioxidants

The Westernization of many developing countries’ diets—diets high in saturated fats, protein, sucrose, salt, and processed foods and low in fresh fruits and green vegetables—has led to a reduced intake of antioxidants and an increase in susceptibility to oxidative damage.27,28 One hypothesis suggests that a reduction in nutritional antioxidants and subsequent oxidative damage leads to airway inflammation that may contribute to an increased prevalence of asthma.27 In vitro data suggest that antioxidant deficiency may influence the differentiation of helper T cells to a TH2 phenotype, which can increase susceptibility to the development of asthma and allergies.29 Vitamin E specifically has been shown to inhibit IL-4 gene expression, which drives type 2 immunity and decreases expression of multiple genes that regulate epidermal barrier function, subsequently increasing susceptibility to allergic inflammation and AD.29,30 Regardless of the proposed mechanisms for antioxidant deficiency increasing susceptibility to allergic disease, studies evaluating the benefits of antioxidant intake during pregnancy in relation to AD have not been promising. Several studies have found no association between prenatal vitamin E intake and the risk for AD development in infants and children.31,32 Another study found a statistically significant inverse relationship between vitamin E intake in mothers with a history of atopy and the development of AD in their children at 2 years of age but not at 1 year of age (P-trend=.024).33 It has been suggested that varying vitamin E isoforms may contribute to the discrepant results previously discussed, with the γ-tocopherol isoform (found frequently in Westernized diets)34 as a driver of inflammation in murine models.35 West et al31 noted an association between vitamin C intake and development of “any allergic disease”—AD, IgE-mediated food allergy, or asthma—with a crude OR of 0.48 (95% CI, 0.25-0.93). However, the P-trend and adjusted OR were not statistically significant. The investigators found no association between maternal intake of beta-carotene, vitamin E, or zinc, but they did find copper supplementation to be protective on the development of AD at 1 year of age (P-trend=0.03). Interestingly, when the data for total antioxidant intake—vitamin C, vitamin E, zinc, beta-carotene, and copper from both diet and supplementation—were combined and analyzed, no statistically significant associations for any of the antioxidants were found.31 Another study of 763 Japanese mother-child pairs found a reduced risk for AD at 16 to 24 months of age with high maternal intake of beta-carotene but found no statistically significant exposure-response associations with other antioxidants, including alpha-carotene, vitamin C, or zinc from dietary intake alone.32 These results were substantiated by 2 meta-analyses evaluating a total of 93 combined intervention trials and cohorts where no association was found between vitamin or mineral intake during pregnancy and/or during infancy and the development of AD.19,36 

Fatty Acids 

Other dietary changes that are associated with an increased prevalence of atopic diseases in children include excess consumption of omega-6 (n-6) long-chain polyunsaturated fatty acids (LC-PUFA) and insufficient omega-3 (n-3) LC-PUFA consumption.37 Given prior evidence that allergic immune responses in infants may be primed before birth,38 researchers have questioned whether the anti-inflammatory properties of n-3 LC-PUFA when supplemented during pregnancy may have immunomodulatory effects on infants that could alter their predisposition to develop allergic disease, including AD.39 A systematic review and meta-analysis of randomized controlled trials found a statistically significant RR of 0.53 (95% CI, 0.35-0.81; P=.004) for the incidence of AD at 12 months of age with maternal supplementation of n-3 LC-PUFA.9 Another trial of 145 pregnant women randomized to supplementation with fish oil vs placebo starting at gestational week 25 and continuing through 3.5 months of breastfeeding found a reduced cumulative incidence of AD in the intervention group compared to controls at 2 years of age, with a statistically significant crude OR of 0.33 (95% CI, 0.11-0.97; P=.04).40 However, the adjusted OR was not statistically significant. In addition, they found that mothers and infants with higher proportions of docosahexaenoic acid and eicosapentaenoic acid in plasma phospholipids have been noted to have a lower prevalence of IgE-associated disease in a dose-dependent manner (P<.05 and P<.05, respectively).40 In another trial of 98 pregnant women randomized to fish oil supplementation or placebo from 20 weeks’ gestation to delivery found no difference in the frequency of AD but did note that infants in the exposure group had significantly less severe AD compared to controls (OR=0.09 [95% CI, 0.1-0.94]; P=.045).39 A prospective birth cohort study of 2641 children evaluated dietary composition during the last 4 weeks of pregnancy and found that consumption of foods rich in n-6 LC-PUFAs (eg, margarine, vegetable oil) increased the risk for developing AD, while foods rich in n-3 LC-PUFAs (eg, fish) decreased the risk for developing AD in offspring at 2 years of age. All P values for margarine, vegetable oil, and fish were statistically significant on logistic regression at P<.05.41 A longitudinal analysis of follow-up data from a randomized controlled trial looking at maternal prenatal n-3 LC-PUFA intake and the development of allergic disease (including AD) found no differences in the development of disease at 1-, 3-, or 6-year follow-up.42 Despite several studies demonstrating a possible benefit of omega-3 fatty acid intake on the development of AD in offspring, the longitudinal analysis by Best et al42 reminds us that long-term follow-up is critical in establishing benefit of any intervention given the heterogeneous and progressive nature of the atopic march and AD. 

Specific Diets 

Several studies have evaluated the role of dietary patterns and their influence on atopic disease. Studies evaluating dietary patterns or supplement intake can be challenging, as data often are derived from questionnaires with bias in response to families with higher socioeconomic status.9 Further, analysis of any one food group does not account for the potential interplay between nutrients.43 Studies should focus more on dietary patterns vs individual foods to assess true risk.43,44 Given these limitations, study results on diet should be carefully scrutinized; however, there are still some positive findings that deserve further investigation. Chatzi et al44 followed 460 children for 6.5 years and found a protective effect for the development of atopy in the offspring of women who had high adherence to the Mediterranean diet (OR 0.55 [95% CI, 0.31-0.97]). Another cohort study evaluating the effects of the Mediterranean diet and risk for AD in the first year of life in 2516 mother-child pairs from Spain and Greece found no statistically significant association with consumption of the Mediterranean diet and AD. The investigators also evaluated intake of fruits, nuts, vegetables, meats, processed meats, dairy products, and cereal and found no statistically significant protective benefit.45 Another systematic review of more than 90 observational studies identified no significant relationship between prenatal dietary exposures of fruits, vegetables, nuts, fat, fatty acids, eggs, cereal, milk, alcohol, tea, or coffee and risk for allergic disease in offspring, including AD.19

 

 

A Chinese prospective cohort study evaluated the dietary protein patterns of 713 mother-child pairs and the incidence of infant AD at 6 months of age.46 Dietary protein patterns were characterized as predominantly poultry, plant based, dairy and eggs, and red meat and fish. The investigators found a statistically significant reduced risk for AD in mothers who consumed plant-based or dairy and eggs protein patterns when compared to a poultry protein pattern with an adjusted OR of 0.572 (95% CI, 0.330-0.992) and 0.478 (95% CI, 0.274-0.837), respectively. This protective effect was not seen with the red meat and fish protein patterns.46 Similar results were seen in a 2020 Canadian study that evaluated the effects of a Western (fats, meats, processed foods, and starchy vegetables), balanced (diverse sources of animal proteins [especially fish], fruits, vegetables, nuts, and seeds), or plant-based (dairy, legumes, vegetables, whole grains, and an aversion to meats) diet in more than 2000 mother-infant pairs from 24 to 28 weeks’ gestation to 1 year of age. The investigators found a lower OR of AD in mothers who followed a mostly plant-based diet compared to other dietary patterns (OR 0.65 [95% CI, 0.55-0.76]; P<.001).10 Another prospective Japanese study looking at healthy (high intake of green and yellow vegetables, seaweed, mushrooms, white vegetables, pulses, potatoes, fish, sea products, fruit, and shellfish, and low intake of confectioneries and soft drinks), Western (high intake of vegetable oil, salt-containing seasonings, beef, pork, processed meat, eggs, chicken, and white vegetables, and low intake of fruit, soft drinks, and confectioneries), or Japanese (high intake of rice, miso soup, sea products, and fish, and low intake of bread, confectioneries, and dairy products) dietary patterns in 763 mother-child pairs found no association between diet during pregnancy and development of AD in offspring at 16 to 24 months.47 Unfortunately, a longitudinal data analysis has not been performed for this study.

Final Thoughts

Atopic dermatitis is a complex, progressive, and heterogeneous disease with both genetic and environmental influences. Studying the effects of diet on the development, progression, or severity of disease can be very difficult due to the heterogeneity of study designs, lack of long-term follow-up, and high potential for residual confounding. Studies evaluating dietary patterns or supplement intake can be equally challenging, as data often are derived from questionnaires with bias in response to families with higher socioeconomic status.9 Very few studies have looked specifically at maternal dietary composition and the development of AD alone (without inclusion of asthma or food allergy). Ultimately, the inconsistency of the data makes it difficult to draw conclusions and make formal recommendations for this vulnerable population. Additional evidence from well-powered trials with comparable methodology and objective outcome measures will be imperative to make formal recommendations. In addition, longitudinal follow-up will be essential to determine long-term benefit and influence on the atopic march.

Atopic dermatitis (AD) is an inflammatory skin disease characterized by skin barrier disruption, skin inflammation, and pruritus.1 It is a common and often chronic skin condition associated with the development of food allergies, asthma, and allergic rhinitis, known as the atopic march.2 Atopic dermatitis is estimated to affect 10% to 25% of children, most with onset before 5 years of age, and up to 7% of adults worldwide.3 Most patients improve with time, but multiple disease trajectories are possible. Several studies have demonstrated that fewer than 4% of children develop the classic atopic march—AD followed by food allergies, asthma, and finally allergic rhinitis—with recent evidence pointing to a more complex heterogeneous progression of disease and allergic comorbidities often occurring together.4,5 The prevalence of AD has been increasing globally over the last 30 years,6 with a marked increase in developed countries.6,7 It is well accepted that AD is based on an interplay between genetic predisposition and environmental factors,8 but many suspect that the rapid rise in prevalence cannot be attributed to genetic factors alone.9 The precipitant triggers for AD remain an area of intense investigation, with ongoing debate between the “inside out” and “outside in” hypotheses; these revolve around whether abnormalities in the immune system trigger barrier dysfunction or barrier dysfunction triggers immune programming to atopy.8 Ongoing research related to genetic predisposition of AD has identified candidate genes implicated in both impaired skin barrier function and altered immune system pathways, further supporting that both theories may contribute to disease pathogenesis. 

The increasing prevalence of AD, with increasing disease burden within socioeconomically advantaged countries, raises the possibility of early modifiable environmental factors that may contribute to the disease process.10 Many studies point to the influence of the 21st century lifestyle and Western diet as primary contributing factors.9,11 However, it is not clear how these factors may influence the development of allergic atopic disease. Several studies have suggested that nonheritable influences in utero can alter fetus immune function and influence the subsequent development of allergic disease.12,13 Although many studies have examined environmental factors contributing to the development of AD in infancy and childhood, less is understood about the influence of prenatal factors. Currently, in utero exposure to tobacco smoke, phthalates, and maternal distress have been potentially implicated in the development of AD.14,15 Several studies have examined the role of maternal diet and nutrition on the development of AD in offspring; however, formal recommendations and robust trial data are lacking. In this article, we examine the existing literature surrounding maternal diet on the development of AD in infancy and childhood.

Allergen Avoidance 

Extrapolating from the food allergy literature, it was once suggested that allergen avoidance in early childhood had a protective effect on the subsequent development of allergies; however, more recent research has found that early exposure to common food allergens, such as peanuts or eggs, may actually reduce a child’s risk for developing these allergies later in life.16 Among infants at high risk for food allergy, sustained consumption of peanut products beginning in the first 11 months of life resulted in an 81% lower rate of peanut allergy at 60 months of age than the rate among children who avoided peanuts.17 Given the results that antigen avoidance during infancy/childhood does not protect against the development of allergies and may actually be counterproductive, it is not surprising that research studying antigen avoidance during pregnancy on the development of AD also has demonstrated limited efficacy. A systematic review of 5 trials on maternal dietary antigen avoidance (N=952) suggested no protective effects of avoiding antigenic foods during pregnancy on the development of AD in the first 18 months of life.18 Another meta-analysis evaluating 12 intervention trials looked at the effects of maternal allergenic food avoidance during pregnancy or lactation and found no reduced risk for subsequent development of allergic disease, including AD.19 The American Academy of Pediatrics 2019 consensus statement does not support maternal dietary restrictions in pregnancy for the prevention of atopic disease and makes note that the data remain limited, which complicates drawing any firm conclusions.20

Probiotic Supplementation 

One of the most investigated dietary supplements for the prevention of atopic disease is probiotics, with possible benefits noted in both the prenatal and postnatal periods. Baquerizo Nole et al21 examined several studies looking at the various benefits of probiotics in AD, which included inhibition of the helper T cell (TH2) response, stimulation of the TH1 response, upregulation of regulatory T cells, acceleration of skin and mucosal barrier function, increase in intestinal microflora diversity, suppression of toxic fermentation products in the intestinal lumen from increased production of short-chain fatty acids, and inhibition of Staphylococcus aureus attachment on epidermal keratinocytes. It is unclear how this may affect infants prenatally; however, transfer of maternal intestinal microflora during delivery and shortly thereafter has demonstrated that probiotic strains remain detectable in the infant’s stool up to 6 months after delivery, even if the mother has discontinued use.22 A 2008 meta-analysis of 10 double-bind, randomized, controlled trials (N=1880) looking at the use of maternal prenatal and postnatal probiotic supplementation in the prevention of pediatric AD found a relative risk (RR) ratio of 0.69 (95% CI, 0.57-0.83) using a fixed effects model and RR ratio of 0.66 (95% CI, 0.49-0.89) using a random effects model. After exclusion of one study that evaluated the effect of postnatal probiotic supplementation only, the RR ratio decreased to 0.61 for both the fixed effects and random effects models.23 A systematic review by Panduru et al24 noted similar findings with a subgroup meta-analysis of 11 studies of prenatal supplementation followed by postnatal supplementation of probiotics, which demonstrated a protective effect on the development of AD (odds ratio [OR]=0.61, P<.001). Postnatal supplementation alone (4 studies) did not have the same association (OR=0.95, P<.82).24 A 2012 meta-analysis by Doege et al25 evaluated 7 randomized, double-blinded, placebo-controlled trials that assessed probiotic supplementation during pregnancy (without incorporation of postnatal supplementation) and found a significant risk reduction of 5.7% (P=.022) for AD in children aged 2 to 7 years. Interestingly, this was only significant for Lactobacillus and not for other bacterial strains, even if a mixture of strains included Lactobacillus. However, Panduru et al24 found both maternal Lactobacillus supplementation alone (8 studies) and in combination with Bifidobacterium (9 studies) was protective against AD development in children (OR=0.70, P=.004; OR=0.62, P<.001). A more recent 2015 meta-analysis of 17 studies (N=4755) evaluating the use of maternal probiotic supplementation in pregnancy and/or through the infant’s first 3 months of life found a significantly lower RR (0.78 [95% CI, 0.69-0.89], P=.0003) for the development of AD in infants treated with probiotics and found this risk to be even further decreased when a mixture of probiotics including both Lactobacillus and Bifidobacterium was used (RR=0.54 [95% CI, 0.43-0.68], P<.00001).26

Antioxidants

The Westernization of many developing countries’ diets—diets high in saturated fats, protein, sucrose, salt, and processed foods and low in fresh fruits and green vegetables—has led to a reduced intake of antioxidants and an increase in susceptibility to oxidative damage.27,28 One hypothesis suggests that a reduction in nutritional antioxidants and subsequent oxidative damage leads to airway inflammation that may contribute to an increased prevalence of asthma.27 In vitro data suggest that antioxidant deficiency may influence the differentiation of helper T cells to a TH2 phenotype, which can increase susceptibility to the development of asthma and allergies.29 Vitamin E specifically has been shown to inhibit IL-4 gene expression, which drives type 2 immunity and decreases expression of multiple genes that regulate epidermal barrier function, subsequently increasing susceptibility to allergic inflammation and AD.29,30 Regardless of the proposed mechanisms for antioxidant deficiency increasing susceptibility to allergic disease, studies evaluating the benefits of antioxidant intake during pregnancy in relation to AD have not been promising. Several studies have found no association between prenatal vitamin E intake and the risk for AD development in infants and children.31,32 Another study found a statistically significant inverse relationship between vitamin E intake in mothers with a history of atopy and the development of AD in their children at 2 years of age but not at 1 year of age (P-trend=.024).33 It has been suggested that varying vitamin E isoforms may contribute to the discrepant results previously discussed, with the γ-tocopherol isoform (found frequently in Westernized diets)34 as a driver of inflammation in murine models.35 West et al31 noted an association between vitamin C intake and development of “any allergic disease”—AD, IgE-mediated food allergy, or asthma—with a crude OR of 0.48 (95% CI, 0.25-0.93). However, the P-trend and adjusted OR were not statistically significant. The investigators found no association between maternal intake of beta-carotene, vitamin E, or zinc, but they did find copper supplementation to be protective on the development of AD at 1 year of age (P-trend=0.03). Interestingly, when the data for total antioxidant intake—vitamin C, vitamin E, zinc, beta-carotene, and copper from both diet and supplementation—were combined and analyzed, no statistically significant associations for any of the antioxidants were found.31 Another study of 763 Japanese mother-child pairs found a reduced risk for AD at 16 to 24 months of age with high maternal intake of beta-carotene but found no statistically significant exposure-response associations with other antioxidants, including alpha-carotene, vitamin C, or zinc from dietary intake alone.32 These results were substantiated by 2 meta-analyses evaluating a total of 93 combined intervention trials and cohorts where no association was found between vitamin or mineral intake during pregnancy and/or during infancy and the development of AD.19,36 

Fatty Acids 

Other dietary changes that are associated with an increased prevalence of atopic diseases in children include excess consumption of omega-6 (n-6) long-chain polyunsaturated fatty acids (LC-PUFA) and insufficient omega-3 (n-3) LC-PUFA consumption.37 Given prior evidence that allergic immune responses in infants may be primed before birth,38 researchers have questioned whether the anti-inflammatory properties of n-3 LC-PUFA when supplemented during pregnancy may have immunomodulatory effects on infants that could alter their predisposition to develop allergic disease, including AD.39 A systematic review and meta-analysis of randomized controlled trials found a statistically significant RR of 0.53 (95% CI, 0.35-0.81; P=.004) for the incidence of AD at 12 months of age with maternal supplementation of n-3 LC-PUFA.9 Another trial of 145 pregnant women randomized to supplementation with fish oil vs placebo starting at gestational week 25 and continuing through 3.5 months of breastfeeding found a reduced cumulative incidence of AD in the intervention group compared to controls at 2 years of age, with a statistically significant crude OR of 0.33 (95% CI, 0.11-0.97; P=.04).40 However, the adjusted OR was not statistically significant. In addition, they found that mothers and infants with higher proportions of docosahexaenoic acid and eicosapentaenoic acid in plasma phospholipids have been noted to have a lower prevalence of IgE-associated disease in a dose-dependent manner (P<.05 and P<.05, respectively).40 In another trial of 98 pregnant women randomized to fish oil supplementation or placebo from 20 weeks’ gestation to delivery found no difference in the frequency of AD but did note that infants in the exposure group had significantly less severe AD compared to controls (OR=0.09 [95% CI, 0.1-0.94]; P=.045).39 A prospective birth cohort study of 2641 children evaluated dietary composition during the last 4 weeks of pregnancy and found that consumption of foods rich in n-6 LC-PUFAs (eg, margarine, vegetable oil) increased the risk for developing AD, while foods rich in n-3 LC-PUFAs (eg, fish) decreased the risk for developing AD in offspring at 2 years of age. All P values for margarine, vegetable oil, and fish were statistically significant on logistic regression at P<.05.41 A longitudinal analysis of follow-up data from a randomized controlled trial looking at maternal prenatal n-3 LC-PUFA intake and the development of allergic disease (including AD) found no differences in the development of disease at 1-, 3-, or 6-year follow-up.42 Despite several studies demonstrating a possible benefit of omega-3 fatty acid intake on the development of AD in offspring, the longitudinal analysis by Best et al42 reminds us that long-term follow-up is critical in establishing benefit of any intervention given the heterogeneous and progressive nature of the atopic march and AD. 

Specific Diets 

Several studies have evaluated the role of dietary patterns and their influence on atopic disease. Studies evaluating dietary patterns or supplement intake can be challenging, as data often are derived from questionnaires with bias in response to families with higher socioeconomic status.9 Further, analysis of any one food group does not account for the potential interplay between nutrients.43 Studies should focus more on dietary patterns vs individual foods to assess true risk.43,44 Given these limitations, study results on diet should be carefully scrutinized; however, there are still some positive findings that deserve further investigation. Chatzi et al44 followed 460 children for 6.5 years and found a protective effect for the development of atopy in the offspring of women who had high adherence to the Mediterranean diet (OR 0.55 [95% CI, 0.31-0.97]). Another cohort study evaluating the effects of the Mediterranean diet and risk for AD in the first year of life in 2516 mother-child pairs from Spain and Greece found no statistically significant association with consumption of the Mediterranean diet and AD. The investigators also evaluated intake of fruits, nuts, vegetables, meats, processed meats, dairy products, and cereal and found no statistically significant protective benefit.45 Another systematic review of more than 90 observational studies identified no significant relationship between prenatal dietary exposures of fruits, vegetables, nuts, fat, fatty acids, eggs, cereal, milk, alcohol, tea, or coffee and risk for allergic disease in offspring, including AD.19

 

 

A Chinese prospective cohort study evaluated the dietary protein patterns of 713 mother-child pairs and the incidence of infant AD at 6 months of age.46 Dietary protein patterns were characterized as predominantly poultry, plant based, dairy and eggs, and red meat and fish. The investigators found a statistically significant reduced risk for AD in mothers who consumed plant-based or dairy and eggs protein patterns when compared to a poultry protein pattern with an adjusted OR of 0.572 (95% CI, 0.330-0.992) and 0.478 (95% CI, 0.274-0.837), respectively. This protective effect was not seen with the red meat and fish protein patterns.46 Similar results were seen in a 2020 Canadian study that evaluated the effects of a Western (fats, meats, processed foods, and starchy vegetables), balanced (diverse sources of animal proteins [especially fish], fruits, vegetables, nuts, and seeds), or plant-based (dairy, legumes, vegetables, whole grains, and an aversion to meats) diet in more than 2000 mother-infant pairs from 24 to 28 weeks’ gestation to 1 year of age. The investigators found a lower OR of AD in mothers who followed a mostly plant-based diet compared to other dietary patterns (OR 0.65 [95% CI, 0.55-0.76]; P<.001).10 Another prospective Japanese study looking at healthy (high intake of green and yellow vegetables, seaweed, mushrooms, white vegetables, pulses, potatoes, fish, sea products, fruit, and shellfish, and low intake of confectioneries and soft drinks), Western (high intake of vegetable oil, salt-containing seasonings, beef, pork, processed meat, eggs, chicken, and white vegetables, and low intake of fruit, soft drinks, and confectioneries), or Japanese (high intake of rice, miso soup, sea products, and fish, and low intake of bread, confectioneries, and dairy products) dietary patterns in 763 mother-child pairs found no association between diet during pregnancy and development of AD in offspring at 16 to 24 months.47 Unfortunately, a longitudinal data analysis has not been performed for this study.

Final Thoughts

Atopic dermatitis is a complex, progressive, and heterogeneous disease with both genetic and environmental influences. Studying the effects of diet on the development, progression, or severity of disease can be very difficult due to the heterogeneity of study designs, lack of long-term follow-up, and high potential for residual confounding. Studies evaluating dietary patterns or supplement intake can be equally challenging, as data often are derived from questionnaires with bias in response to families with higher socioeconomic status.9 Very few studies have looked specifically at maternal dietary composition and the development of AD alone (without inclusion of asthma or food allergy). Ultimately, the inconsistency of the data makes it difficult to draw conclusions and make formal recommendations for this vulnerable population. Additional evidence from well-powered trials with comparable methodology and objective outcome measures will be imperative to make formal recommendations. In addition, longitudinal follow-up will be essential to determine long-term benefit and influence on the atopic march.

References
  1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(suppl 1):8-16.
  2. Kapoor R, Menon C, Hoffstad O, et al. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol. 2008;58:68-73.
  3. Abuabara K, Magyari A, McCulloch CE, et al. Prevalence of atopic eczema among patients seen in primary care: data from the Health Improvement Network. Ann Intern Med. 2019;170:354-356.
  4. Belgrave DC, Granell R, Simpson A, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Medicine. 2014;11:E1001748.
  5. Aguilar D, Pinart M, Koppelman GH, et al. Computational analysis of multimorbidity between asthma, eczema and rhinitis. PloS One. 2017;12:E0179125.
  6. Deckers IA, McLean S, Linssen S, et al. Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies. PloS One. 2012;7:E39803.
  7. Williams H, Stewart A, von Mutius E, et al. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008;121:947-954.
  8. Sullivan M, Silverberg NB. Current and emerging concepts in atopic dermatitis pathogenesis. Clin Dermatol. 2017;35:349-353.
  9. Best KP, Gold M, Kennedy D, et al. Omega-3 long-chain PUFA intake during pregnancy and allergic disease outcomes in the offspring: a systematic review and meta-analysis of observational studies and randomized controlled trials. Am J Clin Nutr. 2016;103:128-143.
  10. Zulyniak MA, de Souza RJ, Shaikh M, et al. Ethnic differences in maternal diet in pregnancy and infant eczema. PloS One. 2020;15:E0232170.
  11. Jena PK, Sheng L, Mcneil K, et al. Long-term Western diet intake leads to dysregulated bile acid signaling and dermatitis with Th2 and Th17 pathway features in mice. J Dermatol Sci. 2019;95:13-20.
  12. Grieger JA, Clifton VL, Tuck AR, et al. In utero programming of allergic susceptibility. Int Arch Allergy Immunol. 2016;169:80-92. doi:10.1159/000443961
  13. Khan TK, Palmer DJ, Prescott SL. In-utero exposures and the evolving epidemiology of paediatric allergy. Curr Opin Allergy Clin Immunol. 2015;15:402-408. doi:10.1097/ACI.0000000000000209
  14. Bauer SM. Atopic eczema: genetic associations and potential links to developmental exposures. Int J Toxicol. 2017;36:187-198.
  15. Shinohara M, Saito H, Matsumoto K. Different timings of prenatal or postnatal tobacco smoke exposure have different effects on the development of atopic eczema/dermatitis syndrome (AEDS) during infancy. J Allergy Clin Immunol. 2012;129:AB40.
  16. Lerodiakonou D, Garcia-Larsen V, Logan A, et al. Timing of allergenic food introduction to the infant diet and risk of allergic or autoimmune disease: a systematic review and meta-analysis. JAMA. 2016;316:1181-1192.
  17. Du Toit G, Roberts G, Sayre PH, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372:803-813.
  18. Kramer MS, Kakuma R. Maternal dietary antigen avoidance during pregnancy or lactation, or both, for preventing or treating atopic disease in the child. Evid Based Child Health. 2014;9:447-483.
  19. Garcia-Larsen V, Ierodiakonou D, Jarrold K, et al. Diet during pregnancy and infancy and risk of allergic or autoimmune disease: a systematic review and meta-analysis. PLoS Med. 2018;15:E1002507.
  20. Greer FR, Sicherer SH, Burks AW; Committee on Nutrition, Section on Allergy and Immunology. The effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics. 2019;143:e20190281.
  21. Baquerizo Nole KL, Yim E, Keri JE. Probiotics and prebiotics in dermatology. J Am Acad Dermatol. 2014;71:814-821.
  22. Schultz M, Göttl C, Young RJ, et al. Administration of oral probiotic bacteria to pregnant women causes temporary infantile colonization. J Pediatr Gastroenterol Nutr. 2004;38:293-297.
  23. Lee J, Seto D, Bielory L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol. 2008;121:116-121.
  24. Panduru M, Panduru NM, Sa˘la˘va˘stru CM, et al. Probiotics and primary prevention of atopic dermatitis: a meta‐analysis of randomized controlled studies. J Eur Acad Dermatol Venereol. 2015;29:232-242.
  25. Doege K, Grajecki D, Zyriax BC, et al. Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood—a meta-analysis. Br J Nutr. 2012;107:1-6.
  26. Zuccotti G, Meneghin F, Aceti A, et al. Probiotics for prevention of atopic diseases in infants: systematic review and meta‐analysis. Allergy. 2015;70:1356-1371.
  27. Seaton A, Godden DJ, Brown K. Increase in asthma: a more toxic environment or a more susceptible population? Thorax. 1994;49:171-174.
  28. Manzel A, Muller DN, Hafler DA, et al. Role of “Western diet” in inflammatory autoimmune diseases. Curr Allergy Asthma Rep. 2014;14:1-8.
  29. Li-Weber M, Giasisi M, Trieber MK, et al. Vitamin E inhibits IL-4 gene expression in peripheral blood T cells. Eur J Immunol. 2002;32:2401-2408.
  30. Sehra S, Yao Y, Howell MD, et al. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol. 2010;184:3186-3190.
  31. West CE, Dunstan J, McCarthy S, et al. Associations between maternal antioxidant intakes in pregnancy and infant allergic outcomes. Nutrients. 2012;4:1747-1758.
  32. Miyake Y, Sasaki S, Tanaka K, et al. Consumption of vegetables, fruit, and antioxidants during pregnancy and wheeze and eczema in infants. Allergy. 2010;65:758-765.
  33. Martindale S, McNeill G, Devereux G, et al. Antioxidant intake in pregnancy in relation to wheeze and eczema in the first two years of life. Am J Respir Crit Care Med. 2005;171:121-128.
  34. Robison R, Kumar R. The effect of prenatal and postnatal dietary exposures on childhood development of atopic disease. Curr Opin Allergy Clin Immunol. 2010;10:139-144.
  35. Berdnikovs S, Abdala-Valencia H, McCary C, et al. Isoforms of vitamin E have opposing immunoregulatory functions during inflammation by regulating leukocyte recruitment. J Immunol. 2009;182:4395-4405.
  36. Beckhaus AA, Garcia‐Marcos L, Forno E, et al. Maternal nutrition during pregnancy and risk of asthma, wheeze, and atopic diseases during childhood: a systematic review and meta‐analysis. Allergy. 2015;70:1588-1604.
  37. Calder PC, Miles EA. Fatty acids and atopic disease. Pediatr Allergy Immunol. 2000;11(suppl 13):29-36.
  38. Prescott S, Macaubas C, Holt B, et al. Transplacental priming of the human immune system to environmental allergens: universal skewing of initial T-cell responses towards Th-2 cytokine profile. J Immunol. 1998;160:4730-4737.
  39. Dunstan JA, Mori TA, Barden A, et al. Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: a randomized, controlled trial. J Allergy Clin Immunol. 2003;112:1178-1184.
  40. Furuhjelm C, Warstedt K, Fagerås M, et al. Allergic disease in infants up to 2 years of age in relation to plasma omega‐3 fatty acids and maternal fish oil supplementation in pregnancy and lactation. Pediatr Allergy Immunol. 2011;22:505-514.
  41. Sausenthaler S, Koletzko S, Schaaf B, et al; LISA Study Group. Maternal diet during pregnancy in relation to eczema and allergic sensitization in the offspring at 2 y of age. Am J Clin Nutr. 2007;85:530-537.
  42. Best KP, Sullivan TR, Palmer DJ, et al. Prenatal omega-3 LCPUFA and symptoms of allergic disease and sensitization throughout early childhood—a longitudinal analysis of long-term follow-up of a randomized controlled trial. World Allergy Organ J. 2018;11:10.
  43. Jacobs DR Jr, Steffen LM. Nutrients, foods, and dietary patterns as exposures in research: a framework for food synergy. Am J Clin Nutr. 2003;78:508-513.
  44. Chatzi L, Torrent M, Romieu I, et al. Mediterranean diet in pregnancy is protective for wheeze and atopy in childhood. Thorax. 2008;63:507-513.
  45. Chatzi L, Garcia R, Roumeliotaki T, et al. Mediterranean diet adherence during pregnancy and risk of wheeze and eczema in the first year of life: INMA (Spain) and RHEA (Greece) mother-child cohort studies. Br J Nutr. 2013;110:2058-2068.
  46. Zeng J, Wu W, Chen Y, et al. Maternal dietary protein patterns during pregnancy and the risk of infant eczema: a cohort study. Front Nutr. 2021;8:294.
  47. Miyake Y, Okubo H, Sasaki S, et al. Maternal dietary patterns during pregnancy and risk of wheeze and eczema in Japanese infants aged 16–24 months: the Osaka Maternal and Child Health Study. Pediatr Allergy Immunol. 2011;22:734-741.
References
  1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(suppl 1):8-16.
  2. Kapoor R, Menon C, Hoffstad O, et al. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol. 2008;58:68-73.
  3. Abuabara K, Magyari A, McCulloch CE, et al. Prevalence of atopic eczema among patients seen in primary care: data from the Health Improvement Network. Ann Intern Med. 2019;170:354-356.
  4. Belgrave DC, Granell R, Simpson A, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Medicine. 2014;11:E1001748.
  5. Aguilar D, Pinart M, Koppelman GH, et al. Computational analysis of multimorbidity between asthma, eczema and rhinitis. PloS One. 2017;12:E0179125.
  6. Deckers IA, McLean S, Linssen S, et al. Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies. PloS One. 2012;7:E39803.
  7. Williams H, Stewart A, von Mutius E, et al. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008;121:947-954.
  8. Sullivan M, Silverberg NB. Current and emerging concepts in atopic dermatitis pathogenesis. Clin Dermatol. 2017;35:349-353.
  9. Best KP, Gold M, Kennedy D, et al. Omega-3 long-chain PUFA intake during pregnancy and allergic disease outcomes in the offspring: a systematic review and meta-analysis of observational studies and randomized controlled trials. Am J Clin Nutr. 2016;103:128-143.
  10. Zulyniak MA, de Souza RJ, Shaikh M, et al. Ethnic differences in maternal diet in pregnancy and infant eczema. PloS One. 2020;15:E0232170.
  11. Jena PK, Sheng L, Mcneil K, et al. Long-term Western diet intake leads to dysregulated bile acid signaling and dermatitis with Th2 and Th17 pathway features in mice. J Dermatol Sci. 2019;95:13-20.
  12. Grieger JA, Clifton VL, Tuck AR, et al. In utero programming of allergic susceptibility. Int Arch Allergy Immunol. 2016;169:80-92. doi:10.1159/000443961
  13. Khan TK, Palmer DJ, Prescott SL. In-utero exposures and the evolving epidemiology of paediatric allergy. Curr Opin Allergy Clin Immunol. 2015;15:402-408. doi:10.1097/ACI.0000000000000209
  14. Bauer SM. Atopic eczema: genetic associations and potential links to developmental exposures. Int J Toxicol. 2017;36:187-198.
  15. Shinohara M, Saito H, Matsumoto K. Different timings of prenatal or postnatal tobacco smoke exposure have different effects on the development of atopic eczema/dermatitis syndrome (AEDS) during infancy. J Allergy Clin Immunol. 2012;129:AB40.
  16. Lerodiakonou D, Garcia-Larsen V, Logan A, et al. Timing of allergenic food introduction to the infant diet and risk of allergic or autoimmune disease: a systematic review and meta-analysis. JAMA. 2016;316:1181-1192.
  17. Du Toit G, Roberts G, Sayre PH, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372:803-813.
  18. Kramer MS, Kakuma R. Maternal dietary antigen avoidance during pregnancy or lactation, or both, for preventing or treating atopic disease in the child. Evid Based Child Health. 2014;9:447-483.
  19. Garcia-Larsen V, Ierodiakonou D, Jarrold K, et al. Diet during pregnancy and infancy and risk of allergic or autoimmune disease: a systematic review and meta-analysis. PLoS Med. 2018;15:E1002507.
  20. Greer FR, Sicherer SH, Burks AW; Committee on Nutrition, Section on Allergy and Immunology. The effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics. 2019;143:e20190281.
  21. Baquerizo Nole KL, Yim E, Keri JE. Probiotics and prebiotics in dermatology. J Am Acad Dermatol. 2014;71:814-821.
  22. Schultz M, Göttl C, Young RJ, et al. Administration of oral probiotic bacteria to pregnant women causes temporary infantile colonization. J Pediatr Gastroenterol Nutr. 2004;38:293-297.
  23. Lee J, Seto D, Bielory L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol. 2008;121:116-121.
  24. Panduru M, Panduru NM, Sa˘la˘va˘stru CM, et al. Probiotics and primary prevention of atopic dermatitis: a meta‐analysis of randomized controlled studies. J Eur Acad Dermatol Venereol. 2015;29:232-242.
  25. Doege K, Grajecki D, Zyriax BC, et al. Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood—a meta-analysis. Br J Nutr. 2012;107:1-6.
  26. Zuccotti G, Meneghin F, Aceti A, et al. Probiotics for prevention of atopic diseases in infants: systematic review and meta‐analysis. Allergy. 2015;70:1356-1371.
  27. Seaton A, Godden DJ, Brown K. Increase in asthma: a more toxic environment or a more susceptible population? Thorax. 1994;49:171-174.
  28. Manzel A, Muller DN, Hafler DA, et al. Role of “Western diet” in inflammatory autoimmune diseases. Curr Allergy Asthma Rep. 2014;14:1-8.
  29. Li-Weber M, Giasisi M, Trieber MK, et al. Vitamin E inhibits IL-4 gene expression in peripheral blood T cells. Eur J Immunol. 2002;32:2401-2408.
  30. Sehra S, Yao Y, Howell MD, et al. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol. 2010;184:3186-3190.
  31. West CE, Dunstan J, McCarthy S, et al. Associations between maternal antioxidant intakes in pregnancy and infant allergic outcomes. Nutrients. 2012;4:1747-1758.
  32. Miyake Y, Sasaki S, Tanaka K, et al. Consumption of vegetables, fruit, and antioxidants during pregnancy and wheeze and eczema in infants. Allergy. 2010;65:758-765.
  33. Martindale S, McNeill G, Devereux G, et al. Antioxidant intake in pregnancy in relation to wheeze and eczema in the first two years of life. Am J Respir Crit Care Med. 2005;171:121-128.
  34. Robison R, Kumar R. The effect of prenatal and postnatal dietary exposures on childhood development of atopic disease. Curr Opin Allergy Clin Immunol. 2010;10:139-144.
  35. Berdnikovs S, Abdala-Valencia H, McCary C, et al. Isoforms of vitamin E have opposing immunoregulatory functions during inflammation by regulating leukocyte recruitment. J Immunol. 2009;182:4395-4405.
  36. Beckhaus AA, Garcia‐Marcos L, Forno E, et al. Maternal nutrition during pregnancy and risk of asthma, wheeze, and atopic diseases during childhood: a systematic review and meta‐analysis. Allergy. 2015;70:1588-1604.
  37. Calder PC, Miles EA. Fatty acids and atopic disease. Pediatr Allergy Immunol. 2000;11(suppl 13):29-36.
  38. Prescott S, Macaubas C, Holt B, et al. Transplacental priming of the human immune system to environmental allergens: universal skewing of initial T-cell responses towards Th-2 cytokine profile. J Immunol. 1998;160:4730-4737.
  39. Dunstan JA, Mori TA, Barden A, et al. Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: a randomized, controlled trial. J Allergy Clin Immunol. 2003;112:1178-1184.
  40. Furuhjelm C, Warstedt K, Fagerås M, et al. Allergic disease in infants up to 2 years of age in relation to plasma omega‐3 fatty acids and maternal fish oil supplementation in pregnancy and lactation. Pediatr Allergy Immunol. 2011;22:505-514.
  41. Sausenthaler S, Koletzko S, Schaaf B, et al; LISA Study Group. Maternal diet during pregnancy in relation to eczema and allergic sensitization in the offspring at 2 y of age. Am J Clin Nutr. 2007;85:530-537.
  42. Best KP, Sullivan TR, Palmer DJ, et al. Prenatal omega-3 LCPUFA and symptoms of allergic disease and sensitization throughout early childhood—a longitudinal analysis of long-term follow-up of a randomized controlled trial. World Allergy Organ J. 2018;11:10.
  43. Jacobs DR Jr, Steffen LM. Nutrients, foods, and dietary patterns as exposures in research: a framework for food synergy. Am J Clin Nutr. 2003;78:508-513.
  44. Chatzi L, Torrent M, Romieu I, et al. Mediterranean diet in pregnancy is protective for wheeze and atopy in childhood. Thorax. 2008;63:507-513.
  45. Chatzi L, Garcia R, Roumeliotaki T, et al. Mediterranean diet adherence during pregnancy and risk of wheeze and eczema in the first year of life: INMA (Spain) and RHEA (Greece) mother-child cohort studies. Br J Nutr. 2013;110:2058-2068.
  46. Zeng J, Wu W, Chen Y, et al. Maternal dietary protein patterns during pregnancy and the risk of infant eczema: a cohort study. Front Nutr. 2021;8:294.
  47. Miyake Y, Okubo H, Sasaki S, et al. Maternal dietary patterns during pregnancy and risk of wheeze and eczema in Japanese infants aged 16–24 months: the Osaka Maternal and Child Health Study. Pediatr Allergy Immunol. 2011;22:734-741.
Issue
Cutis - 109(3)
Issue
Cutis - 109(3)
Page Number
152-156
Page Number
152-156
Publications
Publications
Topics
Article Type
Display Headline
The Impact of Prenatal Nutrition on the Development of Atopic Dermatitis in Infancy and Childhood
Display Headline
The Impact of Prenatal Nutrition on the Development of Atopic Dermatitis in Infancy and Childhood
Sections
Inside the Article

Practice Points

  • The prevalence of atopic dermatitis (AD) has been increasing globally, with a marked increase in developed countries.
  • Maternal dietary restriction is not recommended in pregnancy for the prevention of atopic disease in infancy and childhood based on the existing literature.
  • There is mixed evidence to support probiotic supplementation in the prenatal period.
  • The recommendations supporting antioxidant and fatty acid supplementation as well as specific prenatal diets for the prevention of AD in infants and children are limited due to the heterogeneity of study designs.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Managing overuse of food IgE panels: Multiple approaches needed

Article Type
Changed
Mon, 03/07/2022 - 10:26

 

PHOENIX – For at least a decade, professional allergy and pediatrics societies have urged against using food IgE tests unless the patient has a history consistent with potential IgE-mediated food allergies. Yet virtually every health system offers these blood tests, and their inappropriate use – especially of panels that measure many allergens at once – remains a huge problem.

Beyond wasteful spending, excessive food IgE testing can lead patients to worry needlessly and to avoid foods they aren’t allergic to. For babies and toddlers, avoidance can drive up the risk of developing allergies to those foods later in life – a consequence that was convincingly proven by the LEAP study but has still not translated to a widespread change in practice.

“I think we all know that there’s just a lot of system-wide resistance to making these changes, and we don’t completely understand why,” Nicholas Hartog, MD, an allergist with Spectrum Health in Grand Rapids, Mich., told this news organization.

At the American Academy of Allergy, Asthma & Immunology annual meeting, one of Dr. Hartog’s residents, Courtney Cotter, DO, presented a poster detailing their team’s retrospective review of food panel ordering practices across Spectrum Health, a large, multispecialty physician group in west Michigan.

The team combed Epic health records to evaluate food IgE ordering from January 2016 to December 2021. They tracked monthly figures for the number of patients who underwent food IgE tests, the percentage of tested patients for whom food panels were available, and the number of food panels and total number of food IgE tests ordered. They compared average rates from the final 3 months with rates from the first 3 months, which predated the August 2016 establishment of an academic pediatric allergy/immunology department.

Initially, Dr. Hartog and his colleagues focused on educating doctors on appropriate use of food IgE tests through informal conversations and lectures, but, he said, “It’s really difficult to change physician behavior, so sometimes we have to go about it by making it hard to do the wrong thing.”

To that end, the team tried to eliminate the food panels. However, some lab staff feared the possibility of losing revenue if physicians decided to order these tests elsewhere. After more negotiations, the laboratory agreed in December 2019 to restrict and rework food IgE testing by dropping the number of panels from nine to two and by restricting the number of foods in those panels. For example, in the basic panel, “we limited it to just four allergens, so even if you order a panel, you’re not getting 20 results,” Dr. Hartog told this news organization. “I finally found a friendly pathologist who was very on board with this positive change.”

In December 2020, the team implemented yet another strategy: Epic alerts. Each time doctors request a food panel, they receive a pop-up message stating that panel tests are not recommended and asking if they wish to proceed.

The multipronged effort had a modest impact on the number of food panels ordered per month, which dipped from 112.7 to 84.7 for the first and last 3 months of the study. Monthly totals of individual food IgE tests showed a steeper drop, decreasing from 2,379 to 1,180 in the initial and final 3-month periods – a change Dr. Hartog attributes to the revamped food panels. They estimated the cost savings at around $40 per patient, “and we were getting on average about 200 patients a month, so it adds up,” he said.

But the Epic alerts seemed to have little effect. Over the duration of the study, the monthly number of IgE tests ordered per clinician did not change. Neither did the percentage of patients evaluated with a food panel. “The alerts pop up, but people are still ordering,” Dr. Hartog said.

On the whole, the analysis shows that, “despite major efforts to educate providers and the public about these things, it is rampantly disregarded and is a huge problem for our specialty and is likely causing harm to patients,” said allergist-immunologist Gerald Lee, MD, of Emory University in Atlanta.

Dr. Lee said that a common scenario for inappropriate food IgE testing is severe eczema. Many parents request blood tests because they assume their child’s skin condition is driven by food allergies. When the child turns up positive to various foods on panel tests, which have high false-positive rates, the physician may recommend eliminating those foods to improve the skin rash – which “actually delays introduction of the food and potentially increases the risk for food allergy,” Dr. Lee said. “That was a common practice when I was in fellowship (2011) and is widely prevalent today.”

Edwin Kim, MD, director of the UNC Food Allergy Initiative at the University of North Carolina at Chapel Hill, agrees that food IgE panels are wasteful and harmful. However, he thinks the solution is not to tell primary care physicians and pediatricians to stop using the tests. “We’re insinuating that they’re being used inappropriately, but the problem is that these are people that are patient facing, the patients are asking a question, and the appropriate tests aren’t there,” Dr. Kim said. “A big part of that problem is that the tests we have available to us are not good enough.”

The Spectrum Health analysis did not examine ICD codes associated with the food IgE tests or track which physicians ordered the tests. A 2016 retrospective review published in Pediatrics did evaluate ordering practices by specialty and found that primary care providers ordered “significantly more food allergen panels, tests for uncommon causes of food allergy, and generate higher cost per patient compared with allergists.”

Given the immense challenges with implementing system-wide changes, sometimes it can help to educate parents and families. “When you sit down and take 2 or 3 minutes to explain why this is a bad test and that I care about your kid but just don’t want inappropriate testing, they’re okay with it. They understand,” Dr. Hartog said. “When I teach residents, I make sure to emphasize that we have these conversations all the time.”

Dr. Hartog reports financial relationships with Binding Site (speaker), Regeneron (advisory board), Genentech (advisory board), Horizon Pharmaceuticals (advisory board, consulting, speaker), Takeda (speaker, advisory board) and Pharming Healthcare (advisory board, scientific steering committee, consulting), though none related to food allergy. Dr. Lee has disclosed no relevant financial relationships. Dr. Kim reports consultancy with Aimmune Therapeutics, Allako, AllerGenis, Belhaven Pharma, DBV Technologies, Duke Clinical Research Institute, and Nutricia; advisory board membership with ALK, DBV Technologies, Kenota Health, and Ukko; and grant support from the National Institute of Allergy and Infectious Diseases and the Immune Tolerance Network; the National Center for Complementary and Integrative Health; Food Allergy Research and Education; and the Wallace Research Foundation.

A version of this article first appeared on Medscape.com.

Publications
Topics
Sections

 

PHOENIX – For at least a decade, professional allergy and pediatrics societies have urged against using food IgE tests unless the patient has a history consistent with potential IgE-mediated food allergies. Yet virtually every health system offers these blood tests, and their inappropriate use – especially of panels that measure many allergens at once – remains a huge problem.

Beyond wasteful spending, excessive food IgE testing can lead patients to worry needlessly and to avoid foods they aren’t allergic to. For babies and toddlers, avoidance can drive up the risk of developing allergies to those foods later in life – a consequence that was convincingly proven by the LEAP study but has still not translated to a widespread change in practice.

“I think we all know that there’s just a lot of system-wide resistance to making these changes, and we don’t completely understand why,” Nicholas Hartog, MD, an allergist with Spectrum Health in Grand Rapids, Mich., told this news organization.

At the American Academy of Allergy, Asthma & Immunology annual meeting, one of Dr. Hartog’s residents, Courtney Cotter, DO, presented a poster detailing their team’s retrospective review of food panel ordering practices across Spectrum Health, a large, multispecialty physician group in west Michigan.

The team combed Epic health records to evaluate food IgE ordering from January 2016 to December 2021. They tracked monthly figures for the number of patients who underwent food IgE tests, the percentage of tested patients for whom food panels were available, and the number of food panels and total number of food IgE tests ordered. They compared average rates from the final 3 months with rates from the first 3 months, which predated the August 2016 establishment of an academic pediatric allergy/immunology department.

Initially, Dr. Hartog and his colleagues focused on educating doctors on appropriate use of food IgE tests through informal conversations and lectures, but, he said, “It’s really difficult to change physician behavior, so sometimes we have to go about it by making it hard to do the wrong thing.”

To that end, the team tried to eliminate the food panels. However, some lab staff feared the possibility of losing revenue if physicians decided to order these tests elsewhere. After more negotiations, the laboratory agreed in December 2019 to restrict and rework food IgE testing by dropping the number of panels from nine to two and by restricting the number of foods in those panels. For example, in the basic panel, “we limited it to just four allergens, so even if you order a panel, you’re not getting 20 results,” Dr. Hartog told this news organization. “I finally found a friendly pathologist who was very on board with this positive change.”

In December 2020, the team implemented yet another strategy: Epic alerts. Each time doctors request a food panel, they receive a pop-up message stating that panel tests are not recommended and asking if they wish to proceed.

The multipronged effort had a modest impact on the number of food panels ordered per month, which dipped from 112.7 to 84.7 for the first and last 3 months of the study. Monthly totals of individual food IgE tests showed a steeper drop, decreasing from 2,379 to 1,180 in the initial and final 3-month periods – a change Dr. Hartog attributes to the revamped food panels. They estimated the cost savings at around $40 per patient, “and we were getting on average about 200 patients a month, so it adds up,” he said.

But the Epic alerts seemed to have little effect. Over the duration of the study, the monthly number of IgE tests ordered per clinician did not change. Neither did the percentage of patients evaluated with a food panel. “The alerts pop up, but people are still ordering,” Dr. Hartog said.

On the whole, the analysis shows that, “despite major efforts to educate providers and the public about these things, it is rampantly disregarded and is a huge problem for our specialty and is likely causing harm to patients,” said allergist-immunologist Gerald Lee, MD, of Emory University in Atlanta.

Dr. Lee said that a common scenario for inappropriate food IgE testing is severe eczema. Many parents request blood tests because they assume their child’s skin condition is driven by food allergies. When the child turns up positive to various foods on panel tests, which have high false-positive rates, the physician may recommend eliminating those foods to improve the skin rash – which “actually delays introduction of the food and potentially increases the risk for food allergy,” Dr. Lee said. “That was a common practice when I was in fellowship (2011) and is widely prevalent today.”

Edwin Kim, MD, director of the UNC Food Allergy Initiative at the University of North Carolina at Chapel Hill, agrees that food IgE panels are wasteful and harmful. However, he thinks the solution is not to tell primary care physicians and pediatricians to stop using the tests. “We’re insinuating that they’re being used inappropriately, but the problem is that these are people that are patient facing, the patients are asking a question, and the appropriate tests aren’t there,” Dr. Kim said. “A big part of that problem is that the tests we have available to us are not good enough.”

The Spectrum Health analysis did not examine ICD codes associated with the food IgE tests or track which physicians ordered the tests. A 2016 retrospective review published in Pediatrics did evaluate ordering practices by specialty and found that primary care providers ordered “significantly more food allergen panels, tests for uncommon causes of food allergy, and generate higher cost per patient compared with allergists.”

Given the immense challenges with implementing system-wide changes, sometimes it can help to educate parents and families. “When you sit down and take 2 or 3 minutes to explain why this is a bad test and that I care about your kid but just don’t want inappropriate testing, they’re okay with it. They understand,” Dr. Hartog said. “When I teach residents, I make sure to emphasize that we have these conversations all the time.”

Dr. Hartog reports financial relationships with Binding Site (speaker), Regeneron (advisory board), Genentech (advisory board), Horizon Pharmaceuticals (advisory board, consulting, speaker), Takeda (speaker, advisory board) and Pharming Healthcare (advisory board, scientific steering committee, consulting), though none related to food allergy. Dr. Lee has disclosed no relevant financial relationships. Dr. Kim reports consultancy with Aimmune Therapeutics, Allako, AllerGenis, Belhaven Pharma, DBV Technologies, Duke Clinical Research Institute, and Nutricia; advisory board membership with ALK, DBV Technologies, Kenota Health, and Ukko; and grant support from the National Institute of Allergy and Infectious Diseases and the Immune Tolerance Network; the National Center for Complementary and Integrative Health; Food Allergy Research and Education; and the Wallace Research Foundation.

A version of this article first appeared on Medscape.com.

 

PHOENIX – For at least a decade, professional allergy and pediatrics societies have urged against using food IgE tests unless the patient has a history consistent with potential IgE-mediated food allergies. Yet virtually every health system offers these blood tests, and their inappropriate use – especially of panels that measure many allergens at once – remains a huge problem.

Beyond wasteful spending, excessive food IgE testing can lead patients to worry needlessly and to avoid foods they aren’t allergic to. For babies and toddlers, avoidance can drive up the risk of developing allergies to those foods later in life – a consequence that was convincingly proven by the LEAP study but has still not translated to a widespread change in practice.

“I think we all know that there’s just a lot of system-wide resistance to making these changes, and we don’t completely understand why,” Nicholas Hartog, MD, an allergist with Spectrum Health in Grand Rapids, Mich., told this news organization.

At the American Academy of Allergy, Asthma & Immunology annual meeting, one of Dr. Hartog’s residents, Courtney Cotter, DO, presented a poster detailing their team’s retrospective review of food panel ordering practices across Spectrum Health, a large, multispecialty physician group in west Michigan.

The team combed Epic health records to evaluate food IgE ordering from January 2016 to December 2021. They tracked monthly figures for the number of patients who underwent food IgE tests, the percentage of tested patients for whom food panels were available, and the number of food panels and total number of food IgE tests ordered. They compared average rates from the final 3 months with rates from the first 3 months, which predated the August 2016 establishment of an academic pediatric allergy/immunology department.

Initially, Dr. Hartog and his colleagues focused on educating doctors on appropriate use of food IgE tests through informal conversations and lectures, but, he said, “It’s really difficult to change physician behavior, so sometimes we have to go about it by making it hard to do the wrong thing.”

To that end, the team tried to eliminate the food panels. However, some lab staff feared the possibility of losing revenue if physicians decided to order these tests elsewhere. After more negotiations, the laboratory agreed in December 2019 to restrict and rework food IgE testing by dropping the number of panels from nine to two and by restricting the number of foods in those panels. For example, in the basic panel, “we limited it to just four allergens, so even if you order a panel, you’re not getting 20 results,” Dr. Hartog told this news organization. “I finally found a friendly pathologist who was very on board with this positive change.”

In December 2020, the team implemented yet another strategy: Epic alerts. Each time doctors request a food panel, they receive a pop-up message stating that panel tests are not recommended and asking if they wish to proceed.

The multipronged effort had a modest impact on the number of food panels ordered per month, which dipped from 112.7 to 84.7 for the first and last 3 months of the study. Monthly totals of individual food IgE tests showed a steeper drop, decreasing from 2,379 to 1,180 in the initial and final 3-month periods – a change Dr. Hartog attributes to the revamped food panels. They estimated the cost savings at around $40 per patient, “and we were getting on average about 200 patients a month, so it adds up,” he said.

But the Epic alerts seemed to have little effect. Over the duration of the study, the monthly number of IgE tests ordered per clinician did not change. Neither did the percentage of patients evaluated with a food panel. “The alerts pop up, but people are still ordering,” Dr. Hartog said.

On the whole, the analysis shows that, “despite major efforts to educate providers and the public about these things, it is rampantly disregarded and is a huge problem for our specialty and is likely causing harm to patients,” said allergist-immunologist Gerald Lee, MD, of Emory University in Atlanta.

Dr. Lee said that a common scenario for inappropriate food IgE testing is severe eczema. Many parents request blood tests because they assume their child’s skin condition is driven by food allergies. When the child turns up positive to various foods on panel tests, which have high false-positive rates, the physician may recommend eliminating those foods to improve the skin rash – which “actually delays introduction of the food and potentially increases the risk for food allergy,” Dr. Lee said. “That was a common practice when I was in fellowship (2011) and is widely prevalent today.”

Edwin Kim, MD, director of the UNC Food Allergy Initiative at the University of North Carolina at Chapel Hill, agrees that food IgE panels are wasteful and harmful. However, he thinks the solution is not to tell primary care physicians and pediatricians to stop using the tests. “We’re insinuating that they’re being used inappropriately, but the problem is that these are people that are patient facing, the patients are asking a question, and the appropriate tests aren’t there,” Dr. Kim said. “A big part of that problem is that the tests we have available to us are not good enough.”

The Spectrum Health analysis did not examine ICD codes associated with the food IgE tests or track which physicians ordered the tests. A 2016 retrospective review published in Pediatrics did evaluate ordering practices by specialty and found that primary care providers ordered “significantly more food allergen panels, tests for uncommon causes of food allergy, and generate higher cost per patient compared with allergists.”

Given the immense challenges with implementing system-wide changes, sometimes it can help to educate parents and families. “When you sit down and take 2 or 3 minutes to explain why this is a bad test and that I care about your kid but just don’t want inappropriate testing, they’re okay with it. They understand,” Dr. Hartog said. “When I teach residents, I make sure to emphasize that we have these conversations all the time.”

Dr. Hartog reports financial relationships with Binding Site (speaker), Regeneron (advisory board), Genentech (advisory board), Horizon Pharmaceuticals (advisory board, consulting, speaker), Takeda (speaker, advisory board) and Pharming Healthcare (advisory board, scientific steering committee, consulting), though none related to food allergy. Dr. Lee has disclosed no relevant financial relationships. Dr. Kim reports consultancy with Aimmune Therapeutics, Allako, AllerGenis, Belhaven Pharma, DBV Technologies, Duke Clinical Research Institute, and Nutricia; advisory board membership with ALK, DBV Technologies, Kenota Health, and Ukko; and grant support from the National Institute of Allergy and Infectious Diseases and the Immune Tolerance Network; the National Center for Complementary and Integrative Health; Food Allergy Research and Education; and the Wallace Research Foundation.

A version of this article first appeared on Medscape.com.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article